2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T616,Cirrhosis and hepatocellular carcinoma (HCC) are interconnected outcomes of chronic liver disease, with portal hypertension playing a key part in cirrhosis decompensation, and influencing HCC prognosis and treatment. Despite their overlap, current guidelines address portal hypertension and HCC separately, leading to suboptimal risk stratification and treatment selection. This Review proposes a stage-based, integrated approach to HCC management that incorporates the prognostic stages of cirrhosis and emphasizes clinically significant portal hypertension (CSPH) as a key stratifying factor in compensated cirrhosis. CSPH is associated with an increased risk of cirrhosis decompensation, and its presence often limits the feasibility of curative treatments such as surgical resection. Although CSPH is strictly defined as hepatic venous pressure gradient (HVPG) of ≥10 mmHg, non-invasive tools (liver stiffness and platelet count) have largely replaced HVPG in cirrhosis; in patients with HCC, emerging data suggest that these non-invasive tests are poised to replace HVPG and its traditional surrogates, imaging and endoscopy. We explore the management of both cirrhosis and HCC across all cirrhosis stages - compensated (with or without CSPH), decompensated, and further decompensated - in relation to all HCC stages (very early, early, intermediate and advanced). Future research should validate non-invasive CSPH assessment in HCC and support outcome trials stratified by cirrhosis and HCC stage to guide personalized therapy and improve outcomes.31:T793,In NSCLC, TP53 mutations are heterogeneous with varied effects on protein synthesis, function and clinical outcomes. We hypothesize that a refined classification of TP53 mutations, beyond binary categorization, could improve prognostication. Furthermore, specific mutations could be associated with enhanced benefit from immune checkpoint inhibitors (ICI) versus chemotherapy. To investigate this, we analyzed data from randomized trials (OAK and POPLAR) which compared atezolizumab to chemotherapy in previously treated advanced driver-negative NSCLC. Participants were classified as TP53 mutant or wild-type using baseline plasma, and by coding mutation, and Olivier's and Poeta's classification. We performed multivariable Cox regression analyses to evaluate the prognostic significance of TP53 mutations, and interaction tests to assess their predictive value. Among 762 participants, 49% harbored a TP53 mutation. TP53 mutations based on binary categorization were associated with poorer but not statistically significant OS compared to wild-type (adjusted-HR 1.15; 95 %CI 0.96-1.38; P = .12). However, nonsense mutations classified by coding mutations (adjusted-HR 1.71; 95% CI 1.22-2.39;P = .002), non-missense mutations classified by Olivier's classification (adjusted-HR 1.33; 95% CI 1.03-1.74; P = .03) and disruptive mutations classified by Poeta's classification (adjusted-HR 1.33; 95% CI 1.37-1.77; P = .03) were associated with statistically significant poorer OS. TP53 status did not predict differential benefit from ICI versus chemotherapy (interaction P = .45). In advanced driver-negative NSCLC following progression on first-line chemotherapy, nonsense, non-missense and disruptive mutations of TP53 were strongly associated with inferior OS. These data support utilizing a nuanced classification of TP53 mutations as a stratification factor in future trials, and laboratory reporting to aid prognostication.32:T733,Emerging evidence suggests that circadian timing influences the efficacy of immune checkpoint inhibitors (ICI), with morning infusions associated with improved therapeutic outcomes across various malignancies. However, the impact of ICI infusion timing on extensive-stage small cell lung cancer (ES-SCLC), a disease with poor prognosis and limited therapeutic advancements, remains unexplored. This retrospective study (LungTime-R02) analyzed 397 patients with ES-SCLC who received first-line anti-PD-L1 (atezolizumab or durvalumab) plus chemotherapy at our center between May 2019 and October 2023. The time of day of administration (ToDA) was calculated as the median infusion time for each patient's first four ICI treatment cycles. To assess its prognostic relevance, hazard ratios (HRs) of earlier progression or death were estimated across multiple ToDA thresholds (11:00-16:30). Propensity score matching (1:2) was applied to balance baseline characteristics. Of the 397 patients, the optimal ToDA cutoff for maximizing progression-free survival (PFS) benefit was identified as 15:00, with the lowest HR for PFS observed at this threshold. Patients who received immunochemotherapy before 15:00 exhibited significantly longer PFS and overall survival compared to those treated later, with results consistent across pooled and propensity score matching cohorts. Multivariable analysis confirmed early ToDA as an independent prognostic factor for both PFS (adjusted HR, 0.483; 95% CI, 0.357-0.654) and overall survival (adjusted HR, 0.373; 95% CI, 0.265-0.526). This study provides real-world evidence supporting the survival benefit of earlier immunochemotherapy administration in patients with ES-SCLC. These findings add to the growing body of knowledge on the clinical relevance of circadian timing in cancer treatment. Not applicable.33:Ta71,Abstract Background Emerging evidence suggests that circadian timing influences the efficacy of immune checkpoint inhibitors (ICI), with morning infusions associated with improved therapeutic outcomes across various malignancies. However, the impact of ICI infusion timing on extensive‐stage small cell lung cancer (ES‐SCLC), a disease with poor prognosis and limited therapeutic advancements, remains unexplored. Method This retrospective study (LungTime‐R02) analyzed 397 patients with ES‐SCLC who received first‐line anti–PD‐L1 (atezolizumab or durvalumab) plus chemotherapy at our center between May 2019 and October 2023. The time of day of administration (ToDA) was calculated as the median infusion time for each patient’s first four ICI treatment cycles. To assess its prognostic relevance, hazard ratios (HRs) of earlier progression or death were estimated across multiple ToDA thresholds (11:00–16:30). Propensity score matching (1:2) was applied to balance baseline characteristics. Result Of the 397 patients, the optimal ToDA cutoff for maximizing progression‐free survival (PFS) benefit was identified as 15:00, with the lowest HR for PFS observed at this threshold. Patients who received immunochemotherapy before 15:00 exhibited significantly longer PFS and overall survival compared to those treated later, with results consistent across pooled and propensity score matching cohorts. Multivariable analysis confirmed early ToDA as an independent prognostic factor for both PFS (adjusted HR, 0.483; 95% CI, 0.357–0.654) and overall survival (adjusted HR, 0.373; 95% CI, 0.265–0.526). Conclusion This study provides real‐world evidence supporting the survival benefit of earlier immunochemotherapy administration in patients with ES‐SCLC. These findings add to the growing body of knowledge on the clinical relevance of circadian timing in cancer treatment. CLINICAL TRIAL REGISTRATION Not applicable 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"atezolizumab: generic Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on atezolizumab (generic). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/generic/atezolizumab\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Generics\",\"item\":\"https://www.reachrx.ai/hub/tag/generic\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"atezolizumab\",\"item\":\"https://www.reachrx.ai/hub/tag/generic/atezolizumab\"}]}}"}}]],["$","$L2f",null,{"title":"atezolizumab: Research & Clinical Takeaways","description":"Explore research on atezolizumab (generic) — efficacy, safety, and comparative data.","papers":[{"doi":"10.1016/j.jtho.2026.103957","pmid":"42697609","title":"The Evolution of Immunotherapy Revolution in Lung Cancer: A 20-Year Perspective","journal_title":"Journal of Thoracic Oncology","journal_issn":"1556-0864","published_at":"2026-09-04T00:00:00.000Z","url":"https://doi.org/10.1016/j.jtho.2026.103957","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-16T06:22:48.155Z","updated_at":"2026-09-16T06:22:48.155Z","tags":[{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"brand","value":"Imfinzi","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"brand","value":"Keytruda","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"brand","value":"Libtayo","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"brand","value":"Opdivo","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"brand","value":"Tecentriq","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"category","value":"Respiratory System","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"condition","value":"Lung Cancer","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"condition","value":"Non-Small Cell Lung Cancer","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"condition","value":"Small Cell Lung Cancer","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"generic","value":"atezolizumab","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"generic","value":"cemiplimab","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"generic","value":"durvalumab","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"generic","value":"ipilimumab","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"generic","value":"ivonescimab","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"generic","value":"nivolumab","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"generic","value":"pembrolizumab","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"generic","value":"serplulimab","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"generic","value":"tarlatamab","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"modality","value":"Anti-Angiogenic Therapy","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"modality","value":"Antibody-Drug Conjugate","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"modality","value":"Bispecific T-Cell Engager","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"modality","value":"Chemo-Immunotherapy","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"modality","value":"Immune Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"warning","value":"Sample size tag was omitted as this is a review article aggregating many trials with no single study population.","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"warning","value":"Several cited trials (e.g., HARMONi-2, SKYSCRAPER-01, DeLLphi) are from 2024–2026 and may represent very recent or preliminary data not yet fully peer-validated at time of reading.","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"warning","value":"The PACIFIC subgroup analysis suggesting reduced OS benefit in PD-L1 <1% patients is post hoc and limited by small numbers; clinical interpretation should be cautious.","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103957","tag_type":"warning","value":"This is a narrative review, not a systematic review or meta-analysis—trial selection and emphasis reflect author perspective and may not be exhaustive.","value_numeric":null}],"summaries":{"what_studied":"This 20-year narrative review covers the evolution of immune checkpoint inhibitor (ICI) therapy in lung cancer—both NSCLC and SCLC—across all disease stages, from second-line monotherapy through perioperative strategies, including biomarkers, resistance mechanisms, toxicity, and emerging immunotherapeutic approaches.","key_result":"ICIs have transformed lung cancer outcomes across stages: 5-year OS reached 31.9% with first-line pembrolizumab in PD-L1 ≥50% NSCLC (KEYNOTE-024) vs. ~5% historically; perioperative pembrolizumab (KEYNOTE-671) yielded the first mature OS benefit in resectable NSCLC; consolidation durvalumab in unresectable stage III NSCLC (PACIFIC) achieved 42.9% 5-year OS vs. 29.1% for placebo; and in ES-SCLC, chemoimmunotherapy improved median OS by ~2–5 months (e.g., 12.3 vs. 10.3 months in IMpower133), though long-term survivors remain rare.","limitations":"- Entirely a narrative review; no primary data, meta-analysis, or systematic evidence synthesis—subject to selection bias in trial coverage.\n- Key outstanding questions (optimal ICI duration beyond 2 years, MRD-guided treatment decisions, best strategies for oncogene-driven NSCLC) remain unresolved due to lack of prospective randomized data.\n- Underrepresentation of older adults, patients with comorbidities, and low/middle-income populations in the cited trials limits generalizability.","practice_takeaway":"PD-L1 testing should guide first-line ICI selection in advanced NSCLC, with monotherapy favored at ≥50% and chemo-IO combinations appropriate across all expression levels; stopping ICI at 2 years appears safe based on current retrospective data, though prospective confirmation is lacking.\n\nIn oncogene-driven NSCLC (EGFR, ALK, RET, ROS1), ICIs offer limited benefit and carry serious safety risks when combined with TKIs—targeted therapy-first strategies should be prioritized and concurrent TKI-ICI use avoided outside clinical trials."}},{"doi":"10.1016/s2468-1253(26)00212-8","pmid":"42641632","title":"On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial","journal_title":"The Lancet Gastroenterology & Hepatology","journal_issn":"2468-1253","published_at":"2026-08-25T00:00:00.000Z","url":"https://doi.org/10.1016/s2468-1253(26)00212-8","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-03T06:19:57.310Z","updated_at":"2026-09-03T06:19:57.310Z","tags":[{"paper_doi":"10.1016/s2468-1253(26)00212-8","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00212-8","tag_type":"brand","value":"Avastin","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00212-8","tag_type":"brand","value":"Tecentriq","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00212-8","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00212-8","tag_type":"condition","value":"Hepatocellular Carcinoma","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00212-8","tag_type":"generic","value":"atezolizumab","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00212-8","tag_type":"generic","value":"bevacizumab","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00212-8","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00212-8","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00212-8","tag_type":"modality","value":"Anti-VEGF Antibody","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00212-8","tag_type":"modality","value":"PD-L1 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00212-8","tag_type":"modality","value":"Transarterial Chemoembolisation","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00212-8","tag_type":"sample_size","value":"n=342","value_numeric":342},{"paper_doi":"10.1016/s2468-1253(26)00212-8","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00212-8","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00212-8","tag_type":"warning","value":"Overall survival data are immature at this publication; the OS result (HR 0.96) should be interpreted cautiously and not used as a primary efficacy conclusion.","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00212-8","tag_type":"warning","value":"TACE-PFS is a surrogate endpoint specific to this trial; it is not a universally standardised oncology endpoint, which may complicate cross-trial comparisons.","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00212-8","tag_type":"warning","value":"The brand name 'Tecentriq' is used for atezolizumab; availability and labelling may vary by region.","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00212-8","tag_type":"warning","value":"The trial enrolled almost exclusively Asian patients (90% Chinese, 10% Japanese), which may limit applicability to non-Asian populations.","value_numeric":null}],"summaries":{"what_studied":"This phase 3 RCT (TALENTACE) evaluated on-demand TACE plus atezolizumab (1200 mg IV) and bevacizumab (15 mg/kg IV) every 3 weeks versus on-demand TACE alone in 342 patients with untreated, intermediate-to-high tumour burden unresectable HCC (six-and-twelve score ≥6) across 40 centres in China and Japan, with a median follow-up of 26.25 months.","key_result":"Adding atezolizumab + bevacizumab to on-demand TACE significantly improved TACE-PFS: median 11.30 months vs. 7.03 months (HR 0.71, 95% CI 0.55–0.92; p=0.0089). Overall survival remained immature at the first interim analysis (median ~34.5 vs. ~35.4 months; HR 0.96, 99.62% CI 0.58–1.58), with no significant difference yet observed.","limitations":"- Overall survival data are immature and no OS benefit has been demonstrated at this interim analysis.\n- Trial was conducted exclusively in China and Japan (90% Chinese), limiting generalisability to Western populations.\n- Open-label design introduces potential performance and assessment bias.","practice_takeaway":"For patients with intermediate-to-high tumour burden unresectable HCC, combining on-demand TACE with atezolizumab + bevacizumab meaningfully delays untreatable progression compared to TACE alone. However, an OS benefit has not yet been confirmed—clinicians should weigh the improved TACE-PFS against the added toxicity burden (notably hypertension 14%, thrombocytopenia 14%, and 5 treatment-related deaths) while awaiting mature OS data."}},{"doi":"10.1016/j.lungcan.2026.109590","pmid":"42664544","title":"Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study","journal_title":"Lung Cancer","journal_issn":"0169-5002","published_at":"2026-08-23T00:00:00.000Z","url":"https://doi.org/10.1016/j.lungcan.2026.109590","source_score":6,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-29T06:19:11.203Z","updated_at":"2026-08-29T06:19:11.203Z","tags":[{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"brand","value":"Imfinzi","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"brand","value":"Tagrisso","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"brand","value":"Tecentriq","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"category","value":"Respiratory System","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"condition","value":"EGFR-Mutant Non-Small Cell Lung Cancer","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"condition","value":"Small Cell Lung Cancer Transformation","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"generic","value":"atezolizumab","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"generic","value":"carboplatin","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"generic","value":"durvalumab","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"generic","value":"etoposide","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"generic","value":"osimertinib","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"modality","value":"EGFR Tyrosine Kinase Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"modality","value":"Immune Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"modality","value":"Platinum-Based Chemotherapy","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"sample_size","value":"n=59","value_numeric":59},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"warning","value":"Median PFS2 is reported for the overall post-transformation cohort only; PFS2 by treatment arm is not separately reported in the abstract, limiting comparison of progression-free outcomes between CE alone and CE plus immunotherapy.","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109590","tag_type":"warning","value":"The immunotherapy group was small (n=16) and heterogeneous (three different ICI regimens), which limits confidence in the survival benefit estimate. The 'practice_changing' flag reflects potential clinical impact but should be interpreted cautiously pending prospective validation.","value_numeric":null}],"summaries":{"what_studied":"This multicenter retrospective cohort study (26 centers, 2016–2025) evaluated survival outcomes in 59 patients with biopsy-proven SCLC transformation after EGFR-TKI therapy, comparing carboplatin/etoposide (CE) alone versus CE plus immune checkpoint inhibitors (atezolizumab, durvalumab, or durvalumab/osimertinib) post-transformation.","key_result":"Adding immunotherapy to CE was associated with significantly longer post-transformation median OS-2 (17.0 vs. 9.0 months; HR 0.327, 95% CI 0.139–0.767; p=0.026) and higher ORR (71.4% vs. 37.8%); overall median OS-2 was 11.0 months and median OS from metastatic diagnosis was 38.0 months.","limitations":"- Retrospective design with inherent selection bias; immunotherapy group was small (n=16) and not randomized.\n- Mixed immunotherapy agents (atezolizumab, durvalumab, durvalumab+osimertinib) preclude conclusions about individual regimens.\n- No biomarker data (e.g., PD-L1, TMB) to guide patient selection.","practice_takeaway":"Consider adding an immune checkpoint inhibitor to carboplatin/etoposide for patients with EGFR-mutant NSCLC who undergo SCLC transformation, as this may roughly double post-transformation survival. Systematic re-biopsy at TKI progression is essential to confirm histologic transformation before selecting therapy."}},{"doi":"10.1158/2326-6066.cir-25-1611","pmid":"42360819","title":"Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors","journal_title":"Cancer Immunology Research","journal_issn":"2326-6066","published_at":"2026-08-05T00:00:00.000Z","url":"https://doi.org/10.1158/2326-6066.cir-25-1611","source_score":10,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-11T13:26:22.511Z","updated_at":"2026-08-11T13:26:22.511Z","tags":[{"paper_doi":"10.1158/2326-6066.cir-25-1611","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1158/2326-6066.cir-25-1611","tag_type":"category","value":"Immunology","value_numeric":null},{"paper_doi":"10.1158/2326-6066.cir-25-1611","tag_type":"condition","value":"Advanced Solid Tumors","value_numeric":null},{"paper_doi":"10.1158/2326-6066.cir-25-1611","tag_type":"condition","value":"Metastatic Cancer","value_numeric":null},{"paper_doi":"10.1158/2326-6066.cir-25-1611","tag_type":"generic","value":"atezolizumab","value_numeric":null},{"paper_doi":"10.1158/2326-6066.cir-25-1611","tag_type":"generic","value":"nivolumab","value_numeric":null},{"paper_doi":"10.1158/2326-6066.cir-25-1611","tag_type":"generic","value":"pembrolizumab","value_numeric":null},{"paper_doi":"10.1158/2326-6066.cir-25-1611","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1158/2326-6066.cir-25-1611","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1158/2326-6066.cir-25-1611","tag_type":"modality","value":"PD-1/PD-L1 Inhibitor","value_numeric":null},{"paper_doi":"10.1158/2326-6066.cir-25-1611","tag_type":"sample_size","value":"n=124","value_numeric":124},{"paper_doi":"10.1158/2326-6066.cir-25-1611","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1158/2326-6066.cir-25-1611","tag_type":"study_design","value":"Prospective Cohort Study","value_numeric":null},{"paper_doi":"10.1158/2326-6066.cir-25-1611","tag_type":"warning","value":"Specific anti-PD-1/PD-L1 agents used are not named in the abstract; generic drug tags (pembrolizumab, nivolumab, atezolizumab) are inferred from common clinical practice and may not reflect the actual drugs used in this cohort.","value_numeric":null},{"paper_doi":"10.1158/2326-6066.cir-25-1611","tag_type":"warning","value":"The level of evidence (3) reflects a single prospective cohort without a validation dataset; results should be interpreted as exploratory.","value_numeric":null},{"paper_doi":"10.1158/2326-6066.cir-25-1611","tag_type":"warning","value":"The 'practice_changing' impact flag is applied cautiously — findings are hypothesis-generating and require prospective validation; the cohort is heterogeneous across tumor types.","value_numeric":null}],"summaries":{"what_studied":"This prospective study evaluated peripheral immune signatures — including Th17 cells and cytokines — as biomarkers of excellent response to anti-PD-1/PD-L1 therapy in 124 patients with advanced/metastatic solid tumors, comparing excellent responders (complete response or durable partial response with PFS ≥1 year) to non-excellent responders at baseline and early on-treatment.","key_result":"Excellent responders (30/124, 24.2%) had significantly higher baseline and early on-treatment Th17-associated cytokines (IL-17F, IL-21, IL-23) and lower IL-8 vs. non-responders (p<0.05). Non-responders showed a rise in exhaustion-like Th17 cells (Ki67+TIGIT+) from baseline to early on-treatment (p<0.01), a pattern absent in excellent responders. High baseline IL-17F and IL-23 associated with superior PFS; high baseline IL-8 associated with inferior overall survival.","limitations":"Single-center prospective cohort with a relatively small sample (n=124); patients received heterogeneous regimens (anti-PD-1/PD-L1 alone or in combination), which may confound immune signatures; generalizability across specific tumor types is limited given the pan-solid tumor design.","practice_takeaway":"Baseline peripheral Th17 cytokines (IL-17F, IL-23) and IL-8 may serve as accessible blood-based biomarkers to predict durable ICI benefit — and warrant prospective validation before clinical adoption. Monitor for early on-treatment expansion of exhaustion-like Th17 cells (Ki67+TIGIT+) as a potential signal of non-response."}},{"doi":"10.1200/jco-25-03052","pmid":"42525921","title":"COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer","journal_title":"Journal of Clinical Oncology","journal_issn":"0732-183X","published_at":"2026-07-29T00:00:00.000Z","url":"https://doi.org/10.1200/jco-25-03052","source_score":62,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-04T18:18:09.513Z","updated_at":"2026-08-04T18:18:09.513Z","tags":[{"paper_doi":"10.1200/jco-25-03052","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"brand","value":"Avastin","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"brand","value":"Tecentriq","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"condition","value":"Metastatic Colorectal Cancer","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"condition","value":"Mismatch Repair Deficient / Microsatellite Instability-High Cancer","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"generic","value":"atezolizumab","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"generic","value":"bevacizumab","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"generic","value":"fluorouracil","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"generic","value":"leucovorin","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"generic","value":"oxaliplatin","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"modality","value":"Chemotherapy","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"modality","value":"PD-L1 Inhibitor","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"modality","value":"VEGF Inhibitor","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"sample_size","value":"n=102","value_numeric":102},{"paper_doi":"10.1200/jco-25-03052","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"warning","value":"Atezolizumab (PD-L1 inhibitor) is the comparator, not a currently approved standard (pembrolizumab or nivolumab); extrapolation to PD-1 inhibitor-based regimens should be done with caution.","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"warning","value":"Overall survival data are not reported in the abstract; durability of the PFS benefit is uncertain.","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"warning","value":"The FFX/bev control arm closed early after enrolling only 20 patients due to KEYNOTE-177 results; it was not included in the primary PFS comparison, making this effectively a two-arm analysis.","value_numeric":null},{"paper_doi":"10.1200/jco-25-03052","tag_type":"warning","value":"The study was underpowered relative to its original design due to protocol amendments and early arm closure.","value_numeric":null}],"summaries":{"what_studied":"Phase III RCT (COMMIT/NRG-GI004/SWOG-S1610) comparing atezolizumab monotherapy vs. mFOLFOX6/bevacizumab/atezolizumab (FFX/bev/atezo) as first-line treatment in dMMR/MSI-H metastatic colorectal cancer (n=82 in the two primary comparison arms; 102 total), with a median follow-up of 46 months.","key_result":"FFX/bev/atezo significantly improved PFS over atezolizumab alone (HR 0.439, 95% CI 0.23–0.84; P=.0103); ORR was 86.1% vs. 46%, and 12-month disease control rate was 64.7% vs. 32.4%. Grade ≥3 adverse events occurred in 34/41 patients on the combination vs. 18/41 on atezolizumab monotherapy.","limitations":"- Trial was substantially downsized (from original 3-arm design) after the FFX/bev control arm closed early (n=20) due to KEYNOTE-177 results, limiting generalizability and power.\n- Atezolizumab (anti-PD-L1) is not a standard-of-care agent in this setting; results may not translate directly to PD-1 inhibitors (e.g., pembrolizumab, nivolumab).\n- Small final sample size (n=82 in the two primary arms) limits subgroup analyses and overall conclusions.","practice_takeaway":"Adding mFOLFOX6/bevacizumab to atezolizumab roughly doubled response rates and cut progression risk by ~56% in dMMR/MSI-H mCRC, but the much higher grade ≥3 toxicity burden with the combination (34 vs. 18 patients) must be weighed carefully. These findings support further study of chemo-immunotherapy combinations in this population, but do not yet displace PD-1 inhibitor monotherapy as the established frontline standard."}},{"doi":"10.1016/j.jhep.2026.03.040","pmid":null,"title":"The future of blood-based biomarkers in liver cancer","journal_title":"Journal of Hepatology","journal_issn":"0168-8278","published_at":"2026-07-02T00:00:00.000Z","url":"https://doi.org/10.1016/j.jhep.2026.03.040","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-07-04T13:26:26.506Z","updated_at":"2026-07-06T13:36:15.887Z","tags":[{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"brand","value":"HelioLiver","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"brand","value":"Oncoguard Liver","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"condition","value":"Biliary Tract Cancer","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"condition","value":"Cholangiocarcinoma","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"condition","value":"Hepatocellular Carcinoma","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"generic","value":"alpha-fetoprotein","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"generic","value":"atezolizumab","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"generic","value":"bevacizumab","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"generic","value":"des-gamma-carboxy prothrombin","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"generic","value":"lenvatinib","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"generic","value":"ramucirumab","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"generic","value":"sorafenib","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"modality","value":"Cell-Free DNA","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"modality","value":"Circulating Tumor DNA","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"modality","value":"Extracellular Vesicles","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"modality","value":"FGFR Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"modality","value":"Immunotherapy","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"modality","value":"Liquid Biopsy","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"modality","value":"Methylated DNA Panel","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"modality","value":"MicroRNA","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"modality","value":"Protein Biomarker Panel","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"warning","value":"Multiple authors report significant conflicts of interest with diagnostic and pharmaceutical companies relevant to this review's content.","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"warning","value":"Only the paper title, DOI, journal, and publication date were provided — no abstract, methods, results, or full text were available. No structured summary or tags can be generated without source content. Please provide the abstract or full text for a complete extraction.","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"warning","value":"Several biomarkers discussed (EVs, fragmentomics, metabolomics) are based on small case-control studies and have not been externally validated in large prospective cohorts.","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"warning","value":"The impact_flag 'practice_changing' reflects the review's framing of liquid biopsy's transformative potential, not established RCT-level evidence for most biomarkers discussed.","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"warning","value":"The TRACER RCT (comparing GALAD vs. ultrasound in >5,000 patients) is ongoing; practice-changing conclusions for methylated DNA panels should await its results.","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2026.03.040","tag_type":"warning","value":"This is a narrative review; findings reflect the authors' synthesis of the literature and are subject to selection bias in cited studies.","value_numeric":null}],"summaries":{"what_studied":"This review covers blood-based biomarkers for hepatocellular carcinoma (HCC) and biliary tract cancers (BTC/CCA) across the full cancer care continuum — risk stratification, surveillance, early detection, prognostication, treatment selection, and minimal residual disease (MRD) monitoring.","key_result":"Few biomarkers have reached routine clinical practice. AFP (alone or combined with ultrasound) and multi-marker panels (GALAD, GAAD, ASAP) show pooled early-stage HCC sensitivity of 70–74% and specificity of 83–87%. Methylated DNA panels (HelioLiver, Oncoguard® Liver) outperform ultrasound for early-stage HCC detection (sensitivity 48–73% vs. 22–29% for ultrasound). For CCA, ctDNA liquid biopsy detects actionable alterations in ~44% of advanced BTC cases; concordance with tissue for IDH1/BRAF is 87–100%, but complex alterations (fusions, CNVs) are less reliably detected. ctDNA positivity after resection predicts recurrence in HCC (HR 2.2–27) and eCCA (HR 1.8–7.7).","limitations":"Most candidate biomarkers are validated only in small, retrospective, or case-control cohorts, with significant spectrum bias (exclusion of indeterminate lesions inflates performance). Technical variability across platforms, lack of standardised EV isolation and ctDNA quantification protocols, and biological confounding from underlying chronic liver disease all limit reproducibility and cross-study comparison.","practice_takeaway":"For HCC surveillance, adding AFP to ultrasound improves sensitivity; methylated DNA panel tests (HelioLiver, Oncoguard® Liver) are promising adjuncts but await prospective RCT validation (TRACER trial ongoing). For advanced BTC, when tissue is unavailable or insufficient, plasma cfDNA with high-quality assays can identify actionable targets (FGFR2, IDH1, BRAF), and liquid biopsy is also useful for detecting acquired resistance mutations during FGFR inhibitor therapy."}},{"doi":"10.1038/s41568-026-00950-y","pmid":"42373751","title":"Imaging the hallmarks of cancer","journal_title":"Nature Reviews Cancer","journal_issn":"1474-175X","published_at":"2026-06-29T00:00:00.000Z","url":"https://doi.org/10.1038/s41568-026-00950-y","source_score":72,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-07T13:26:15.358Z","updated_at":"2026-07-07T13:26:15.358Z","tags":[{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"brand","value":"Lutathera","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"condition","value":"Breast Cancer","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"condition","value":"Cancer","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"condition","value":"Glioblastoma","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"condition","value":"Melanoma","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"condition","value":"Neuroendocrine Tumors","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"condition","value":"Non-Small Cell Lung Cancer","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"condition","value":"Prostate Cancer","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"generic","value":"5-aminolevulinic acid","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"generic","value":"atezolizumab","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"generic","value":"fluorodeoxyglucose F-18","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"generic","value":"lutetium Lu-177 dotatate","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"generic","value":"lutetium Lu-177 PSMA-617","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"generic","value":"pafolacianine","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"modality","value":"Fluorescence-Guided Imaging","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"modality","value":"Immune Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"modality","value":"Magnetic Resonance Imaging","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"modality","value":"Optoacoustic Imaging","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"modality","value":"Positron Emission Tomography","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"modality","value":"Radiomics","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"modality","value":"Radiopharmaceutical Therapy","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"modality","value":"Ultrasound","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"warning","value":"Full text was inaccessible; all extracted content is based on the abstract, reference list, glossary, and publisher page — key data, figures, and tables could not be reviewed.","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"warning","value":"Study design tagged as 'Narrative Review' based on abstract language; no systematic search strategy or PRISMA methodology was described, so formal classification as a systematic review is not supported.","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00950-y","tag_type":"warning","value":"The paper is dated June 2026 and cites several articles from 2025–2026, including some that may themselves be preprints or early publications; clinical readiness of some discussed technologies may change rapidly.","value_numeric":null}],"summaries":{"what_studied":"This review evaluates non-invasive diagnostic imaging technologies mapped to the hallmarks of cancer framework — covering PET, MRI, ultrasound, optoacoustics, and fluorescence imaging — as tools to detect, monitor, and stratify tumors across the full spectrum of cancer biology.","key_result":"Multiple hallmarks can now be imaged directly (e.g., HER2/PSMA/KRAS via PET probes, tumor metabolism via FDG-PET and hyperpolarized ¹³C-MRI, immune checkpoints via PD-L1 PET) or indirectly (e.g., angiogenesis via DCE-MRI, tumor stiffness via elastography); AI-assisted radiomics and radiogenomics further enable non-invasive molecular subtyping and therapy response prediction.","limitations":"- Full text was not accessible; the summary is based on the abstract and publisher page text, which may omit key findings, nuance, or data tables.\n- As a narrative review, it does not provide pooled effect sizes or systematic quality assessments.\n- Clinical translation of many described techniques remains early-phase or investigational.","practice_takeaway":"Clinicians should be aware that a growing toolkit of hallmark-targeted imaging agents (e.g., PSMA-PET, CD8-PET, hyperpolarized ¹³C-MRI, PD-L1 PET) can guide treatment selection, monitor immunotherapy responses, and detect tumor heterogeneity non-invasively. AI-based radiomics tools are increasingly validated for predicting molecular status (e.g., EGFR, KRAS, HRD) from standard imaging, with direct implications for therapy stratification."}},{"doi":"10.1016/s2468-1253(26)00115-9","pmid":"42330996","title":"Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2–3 trial","journal_title":"The Lancet Gastroenterology & Hepatology","journal_issn":"2468-1253","published_at":"2026-06-22T00:00:00.000Z","url":"https://doi.org/10.1016/s2468-1253(26)00115-9","source_score":12,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-26T13:25:23.413Z","updated_at":"2026-06-26T13:25:23.413Z","tags":[{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"brand","value":"Avastin","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"brand","value":"Tecentriq","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"brand","value":"Yervoy","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"condition","value":"Hepatocellular Carcinoma","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"generic","value":"atezolizumab","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"generic","value":"bevacizumab","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"generic","value":"ipilimumab","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"modality","value":"CTLA-4 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"modality","value":"PD-L1 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"modality","value":"VEGF Inhibitor","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"sample_size","value":"n=226","value_numeric":226},{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"warning","value":"91% of enrolled patients were male, which may limit generalisability to female patients with HCC.","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"warning","value":"Brand name for atezolizumab (Tecentriq) has been associated with a withdrawal from some markets; clinicians should verify current availability.","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00115-9","tag_type":"warning","value":"The trial is phase 2 non-comparative — no formal statistical comparison between arms was performed; the stopping rule was based solely on a response threshold in the experimental arm.","value_numeric":null}],"summaries":{"what_studied":"This randomised, open-label, phase 2–3 trial (PRODIGE 81-FFCD 2101-TRIPLET HCC) evaluated whether adding ipilimumab 1 mg/kg (up to 4 doses) to standard atezolizumab 1200 mg plus bevacizumab 15 mg/kg (every 3 weeks, up to 2 years) improved objective response at 24 weeks in 226 treatment-naive adults with unresectable HCC and Child-Pugh A disease across 36 French hospitals (March 2023–September 2024).","key_result":"At 24 weeks, the triple combination arm achieved an objective response rate of 30% (34/113 patients; 80% CI 24–36), falling short of the pre-specified threshold of 35 responders needed to advance to phase 3; the control arm (atezolizumab + bevacizumab) had a 27% ORR (31/113). Treatment-related deaths occurred in 6 (5%) patients in the triple arm vs. none in the control arm.","limitations":"- Phase 2 non-comparative design limits conclusions about superiority or inferiority between arms.\n- Low ipilimumab dose (1 mg/kg) may not have been sufficient for meaningful CTLA-4 blockade in this setting.\n- Single-country (France) enrolment may limit generalisability.","practice_takeaway":"Adding low-dose ipilimumab (1 mg/kg) to atezolizumab plus bevacizumab does not improve response rates and adds treatment-related mortality (5% vs. 0%) in first-line unresectable HCC — this triple combination should not be adopted in clinical practice."}},{"doi":"10.1016/j.ygyno.2026.06.003","pmid":"42284713","title":"Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study","journal_title":"Gynecologic Oncology","journal_issn":"0090-8258","published_at":"2026-06-12T00:00:00.000Z","url":"https://doi.org/10.1016/j.ygyno.2026.06.003","source_score":1,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-21T13:29:50.328Z","updated_at":"2026-06-21T13:29:50.328Z","tags":[{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"brand","value":"Tecentriq","value_numeric":null},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"category","value":"Obstetrics & Gynecology","value_numeric":null},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"condition","value":"Epithelial Ovarian Cancer","value_numeric":null},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"condition","value":"Fallopian Tube Cancer","value_numeric":null},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"condition","value":"Primary Peritoneal Cancer","value_numeric":null},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"generic","value":"atezolizumab","value_numeric":null},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"generic","value":"bevacizumab","value_numeric":null},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"generic","value":"carboplatin","value_numeric":null},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"generic","value":"paclitaxel","value_numeric":null},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"modality","value":"Immune Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"modality","value":"Platinum-Based Chemotherapy","value_numeric":null},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"modality","value":"Taxane","value_numeric":null},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"sample_size","value":"n=18","value_numeric":18},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"study_design","value":"Single-Arm Phase II Pilot Study","value_numeric":null},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"warning","value":"Bevacizumab and PARP inhibitor use post-ICS was optional, introducing heterogeneity in the maintenance phase that may affect translational biomarker interpretation.","value_numeric":null},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"warning","value":"No control arm was included, so comparative efficacy versus standard NACT alone cannot be assessed.","value_numeric":null},{"paper_doi":"10.1016/j.ygyno.2026.06.003","tag_type":"warning","value":"Trial was terminated early (18/40 patients enrolled) due to negative results from the IMagyn050 trial; efficacy conclusions are not reliable at this sample size.","value_numeric":null}],"summaries":{"what_studied":"This phase II pilot study (AdORN) evaluated the safety and feasibility of adding atezolizumab to neoadjuvant carboplatin/paclitaxel in 18 patients with newly diagnosed high-grade stage III/IV epithelial ovarian cancer (EOC) planned for interval cytoreductive surgery (ICS), with translational immune biomarker assessment.","key_result":"Atezolizumab did not delay ICS in any patient due to immunotherapy-related toxicity (only 1 ICS delay occurred from thromboembolism). Optimal cytoreduction was achieved in 13/15 patients (86%); 9/15 (60%) had partial response and 6/15 (40%) had stable disease. Responders showed elevated post-treatment CXCL10, TNFα, and IL-10 versus stable disease patients.","limitations":"- Early termination after enrolling only 18 of 40 planned patients (triggered by negative IMagyn050 trial results), severely limiting statistical power.\n- No comparator arm; single-arm design prevents efficacy conclusions.\n- Predominantly white (78%), older (median age 69) cohort limits generalizability.","practice_takeaway":"Adding atezolizumab to NACT appears feasible without meaningfully delaying surgery, but the trial was underpowered and no efficacy signal can be confirmed. Clinicians should not adopt this regimen outside a trial setting given the negative context of the larger IMagyn050 study."}},{"doi":"10.1016/j.jhepr.2026.101915","pmid":"42276190","title":"Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma","journal_title":"JHEP Reports","journal_issn":"2589-5559","published_at":"2026-06-12T00:00:00.000Z","url":"https://doi.org/10.1016/j.jhepr.2026.101915","source_score":10,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-15T13:21:54.935Z","updated_at":"2026-06-15T13:21:54.935Z","tags":[{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"brand","value":"Avastin","value_numeric":null},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"brand","value":"Nexavar","value_numeric":null},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"brand","value":"Tecentriq","value_numeric":null},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"condition","value":"Hepatocellular Carcinoma","value_numeric":null},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"condition","value":"Liver Cirrhosis","value_numeric":null},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"generic","value":"atezolizumab","value_numeric":null},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"generic","value":"bevacizumab","value_numeric":null},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"generic","value":"sorafenib","value_numeric":null},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"modality","value":"Multikinase Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"modality","value":"PD-L1 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"modality","value":"VEGF Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"sample_size","value":"n=1499","value_numeric":1499},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"warning","value":"Child-Pugh B9 patients represent only 6.5% of the Child-Pugh B cohort; conclusions may not generalize to the most severely impaired patients.","value_numeric":null},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"warning","value":"The 'impact_flag' of practice_changing is applied cautiously given the retrospective design — prospective validation is explicitly called for by the authors.","value_numeric":null},{"paper_doi":"10.1016/j.jhepr.2026.101915","tag_type":"warning","value":"The sorafenib control group was not randomized or formally matched; OS comparisons between A/B and sorafenib should be interpreted with caution due to potential confounding.","value_numeric":null}],"summaries":{"what_studied":"This retrospective international multicenter study evaluated clinical predictors of response to first-line atezolizumab/bevacizumab (A/B) in 246 Child-Pugh B patients with unresectable HCC (out of 1,499 total), treated across 12 centers from 2020–2024, with a sorafenib-treated Child-Pugh B cohort as control.","key_result":"Median OS was 8.1 months (Child-Pugh B) vs. 16.8 months (Child-Pugh A; p<0.001); A/B outperformed sorafenib in Child-Pugh B (p=0.002). A composite score of ALBI grade 1/2 + no extrahepatic metastasis identified three prognostic subgroups with median OS of 10.3, 7.9, and 4.2 months (p<0.0001). Child-Pugh class improved to A in 31% of B patients, linked to treatment of underlying liver disease.","limitations":"Retrospective design limits causal inference. The sorafenib control group was not matched or randomized, introducing potential selection bias. Child-Pugh B9 patients were underrepresented (6.5%), limiting conclusions for the most impaired subgroup.","practice_takeaway":"In Child-Pugh B patients with HCC, consider first-line atezolizumab/bevacizumab preferentially for those with ALBI grade 1/2 and no extrahepatic metastases — this subgroup shows the most meaningful benefit. Actively treating the underlying liver disease (e.g., viral hepatitis, alcohol) alongside systemic therapy may improve hepatic function and outcomes."}},{"doi":"10.1007/s00520-026-10794-9","pmid":"42213142","title":"Treatment and outcomes of immunotherapy related colitis and hepatitis- a multi-centre cohort study in the United Kingdom by the National Oncology Trainee Collaborative for Healthcare Research (NOTCH)","journal_title":"Supportive Care in Cancer","journal_issn":"0941-4355","published_at":"2026-05-29T00:00:00.000Z","url":"https://doi.org/10.1007/s00520-026-10794-9","source_score":10,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-07T13:26:31.261Z","updated_at":"2026-06-07T13:26:31.261Z","tags":[{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"brand","value":"Keytruda","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"brand","value":"Opdivo","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"brand","value":"Remicade","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"brand","value":"Tecentriq","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"brand","value":"Yervoy","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"condition","value":"Immune Checkpoint Inhibitor-Related Colitis","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"condition","value":"Immune Checkpoint Inhibitor-Related Hepatitis","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"condition","value":"Malignant Melanoma","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"condition","value":"Non-Small Cell Lung Cancer","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"condition","value":"Renal Cell Carcinoma","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"generic","value":"atezolizumab","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"generic","value":"infliximab","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"generic","value":"ipilimumab","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"generic","value":"methotrexate","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"generic","value":"mycophenolate mofetil","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"generic","value":"nivolumab","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"generic","value":"pembrolizumab","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"generic","value":"tacrolimus","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"modality","value":"Antimetabolite Immunosuppressant","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"modality","value":"Anti-TNF Agent","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"modality","value":"Calcineurin Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"modality","value":"Corticosteroid","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"modality","value":"Immune Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"sample_size","value":"n=2049","value_numeric":2049},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"warning","value":"Combination ICI (ipilimumab/nivolumab) was used exclusively in the melanoma subgroup, which may confound cancer-type comparisons for GI-irAE risk and survival.","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"warning","value":"The study period (2016–2018) predates wider adoption of newer ICI combinations (e.g., ICI+VEGF inhibitors, ICI+chemotherapy), so findings may not fully apply to current regimens.","value_numeric":null},{"paper_doi":"10.1007/s00520-026-10794-9","tag_type":"warning","value":"The survival benefit associated with IS use in hepatitis should be interpreted cautiously — patients requiring IS may reflect a subgroup with more robust immune activation and underlying treatment response rather than a direct IS effect.","value_numeric":null}],"summaries":{"what_studied":"This retrospective multi-centre cohort study across 12 UK NHS centres evaluated the incidence of, risk factors for, and survival impact of ICI-related colitis and hepatitis (grade ≥2) in 2,049 adults with metastatic melanoma, NSCLC, or RCC treated between June 2016 and June 2018.","key_result":"Colitis occurred in 9.3% (191/1,649) and hepatitis in 6.9% (142/1,649) of patients. Both were linked to improved OS vs. no irAEs (colitis HR 0.42, hepatitis HR 0.50; p<0.0001). Second-line immunosuppressants (IS) were needed in 22.3% of colitis and 15.8% of hepatitis cases. IS did not worsen OS in colitis (HR 0.65, p=0.245) and was associated with improved OS in hepatitis (HR 0.22, p=0.021).","limitations":"- Retrospective design introduces selection bias and variable data quality across sites.\n- Data are historical (2016–2018), so newer ICI agents and combination regimens are not represented.\n- Concurrent hepatotoxic medications (e.g., acetaminophen, statins) were not captured, potentially confounding hepatitis attribution.","practice_takeaway":"Clinicians can reassure patients that using steroids and second-line IS (infliximab for colitis, MMF for hepatitis) does not reduce survival and may improve it in hepatitis — supporting prompt escalation to IS in steroid-refractory cases. Pre-existing autoimmune disease and combination ICI therapy should prompt closer monitoring for colitis; younger patients and melanoma diagnosis warrant heightened liver function surveillance."}},{"doi":"10.1016/j.lungcan.2026.109452","pmid":null,"title":"Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies","journal_title":"Lung Cancer","journal_issn":"0169-5002","published_at":"2026-05-12T00:00:00.000Z","url":"https://doi.org/10.1016/j.lungcan.2026.109452","source_score":4,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-05-19T13:22:50.889Z","updated_at":"2026-05-19T13:22:50.889Z","tags":[{"paper_doi":"10.1016/j.lungcan.2026.109452","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109452","tag_type":"brand","value":"Tecentriq","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109452","tag_type":"category","value":"Respiratory System","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109452","tag_type":"condition","value":"Non-Small Cell Lung Cancer","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109452","tag_type":"generic","value":"atezolizumab","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109452","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109452","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109452","tag_type":"modality","value":"PD-L1 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109452","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109452","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109452","tag_type":"warning","value":"Sample size could not be determined from the provided information and has been omitted.","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109452","tag_type":"warning","value":"The impact_flag 'practice_changing' is inferred from the clinical significance of validating a SC route across all NSCLC stages, but should be confirmed once full numerical results are reviewed.","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109452","tag_type":"warning","value":"The paper was published on 2026-05-12, just one week before today's date — full-text data including specific efficacy numbers, PK ratios, and adverse event rates were not provided in the input; summary is based on title, study names, and general framing only.","value_numeric":null}],"summaries":{"what_studied":"Two randomized studies (IMscin001 and IMscin002) evaluated the efficacy and safety of subcutaneous (SC) vs. intravenous (IV) atezolizumab in patients with non-small cell lung cancer (NSCLC), spanning early-stage, locally advanced, and metastatic disease settings.","key_result":"Updated results confirmed that SC atezolizumab produced pharmacokinetic exposure and clinical outcomes (efficacy and safety) comparable to IV administration across NSCLC disease stages, supporting non-inferiority of the SC route.","limitations":"Full numerical data (e.g., exact PK ratios, survival curves, adverse event rates) are not available from the provided abstract alone; findings rely on two separate trials with potentially different patient populations across disease stages.","practice_takeaway":"SC atezolizumab appears to be a viable alternative to IV infusion in NSCLC, potentially reducing chair time and improving patient convenience. Clinicians can consider SC administration across early-stage through metastatic NSCLC settings."}},{"doi":"10.1016/j.ekir.2026.106529","pmid":"42112157","title":"Single-Center Perspective of Glomerular Pathology in Patients Treated with Checkpoint Inhibitors","journal_title":"Kidney International Reports","journal_issn":"2468-0249","published_at":"2026-05-11T00:00:00.000Z","url":"https://doi.org/10.1016/j.ekir.2026.106529","source_score":14,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-05-11","doi":"10.1016/j.ekir.2026.106529","days":"7","issn":"2468-0249","rank":"7","field":"Clinical Medicine","score":"14","category":"Urology & Nephrology","categories":["Urology & Nephrology"],"_categories":["Urology & Nephrology"]},"pubmed":{"doi":"10.1016/j.ekir.2026.106529","title":"Single-Center Perspective of Glomerular Pathology in Patients Treated with Checkpoint Inhibitors.","journal":"Kidney international reports","methods":"","results":"","abstract":"","keywords":["glomerular disease","immune checkpoint inhibitor","kidney biopsy","nephrotoxicity","thrombotic microangiopathy"],"pubmed_id":"42112157","conclusions":"","publication_date":"2026-05-11T00:00:00"},"crossref":{"DOI":"10.1016/j.ekir.2026.106529","URL":"https://doi.org/10.1016/j.ekir.2026.106529","ISSN":["2468-0249"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S2468024926027610?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S2468024926027610?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"106529","type":"journal-article","issue":"6","score":1,"title":["Single-Center Perspective of Glomerular Pathology in Patients Treated with Checkpoint Inhibitors"],"author":[{"given":"Arjunmohan","family":"Mohan","sequence":"first","affiliation":[]},{"given":"Cristina","family":"Riaza-Ortiz","sequence":"additional","affiliation":[]},{"given":"Belinda","family":"Galeano","sequence":"additional","affiliation":[]},{"given":"Salvatore","family":"Mignano","sequence":"additional","affiliation":[]},{"given":"Sam T.","family":"Albadri","sequence":"additional","affiliation":[]},{"given":"Alessia","family":"Buglioni","sequence":"additional","affiliation":[]},{"given":"Mariam P.","family":"Alexander","sequence":"additional","affiliation":[]},{"given":"Sandra M.","family":"Herrmann","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/100007048","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100007048","name":"Mayo Clinic","award":["UL1TR002377"],"award-info":[{"award-number":["UL1TR002377"]}],"doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2026,6]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":"11","created":{"date-time":"2026-04-06T17:08:43Z","timestamp":1775495323000,"date-parts":[[2026,4,6]]},"indexed":{"date-time":"2026-05-06T21:14:42Z","timestamp":1778102082468,"date-parts":[[2026,5,6]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000,"date-parts":[[2026,6,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000,"date-parts":[[2026,6,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"http://creativecommons.org/licenses/by-nc-nd/4.0/","start":{"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000,"date-parts":[[2026,3,26]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S2468024926027610"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Single-Center Perspective of Glomerular Pathology in Patients Treated with Checkpoint Inhibitors"},{"name":"journaltitle","label":"Journal Title","value":"Kidney International Reports"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.ekir.2026.106529"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2026 The Author(s). Published by Elsevier Inc. on behalf of the International Society of Nephrology."}],"deposited":{"date-time":"2026-05-06T20:53:47Z","timestamp":1778100827000,"date-parts":[[2026,5,6]]},"issn-type":[{"type":"print","value":"2468-0249"}],"published":{"date-parts":[[2026,6]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.1016/j.kint.2024.09.017","key":"10.1016/j.ekir.2026.106529_bib1","year":"2025","issue":null,"author":"Herrmann","volume":"107","first-page":"21","unstructured":null,"article-title":"Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-Nephrology","journal-title":"Kidney Int","doi-asserted-by":"crossref"},{"DOI":"10.1681/ASN.2019070676","key":"10.1016/j.ekir.2026.106529_bib2","year":"2020","issue":null,"author":"Cortazar","volume":"31","first-page":"435","unstructured":null,"article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","journal-title":"J Am Soc Nephrol","doi-asserted-by":"crossref"},{"DOI":"10.1080/0886022X.2022.2147439","key":"10.1016/j.ekir.2026.106529_bib3","year":"2022","issue":null,"author":"He","volume":"44","first-page":"2046","unstructured":null,"article-title":"Glomerular diseases after immune checkpoint inhibitors use: what do We know so far?","journal-title":"Ren Fail","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ekir.2020.10.002","key":"10.1016/j.ekir.2026.106529_bib4","year":"2021","issue":null,"author":"Kitchlu","volume":"6","first-page":"66","unstructured":null,"article-title":"A systematic review of immune checkpoint inhibitor-associated glomerular disease","journal-title":"Kidney Int Rep","doi-asserted-by":"crossref"},{"DOI":"10.1186/s40425-018-0478-8","key":"10.1016/j.ekir.2026.106529_bib5","year":"2019","issue":null,"author":"Mamlouk","volume":"7","first-page":"2","unstructured":null,"article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","journal-title":"J Immunother Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa0707330","key":"10.1016/j.ekir.2026.106529_bib6","year":"2008","issue":null,"author":"Eremina","volume":"358","first-page":"1129","unstructured":null,"article-title":"VEGF inhibition and renal thrombotic microangiopathy","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ekir.2025.08.011","key":"10.1016/j.ekir.2026.106529_bib7","year":"2025","issue":null,"author":"Barbir","volume":"10","first-page":"3707","unstructured":null,"article-title":"Complement inhibition enables antivascular endothelial growth factor receptor therapy in renal-limited thrombotic microangiopathy","journal-title":"Kidney Int Rep","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.ajkd.2019.04.016","key":"10.1016/j.ekir.2026.106529_bib8","year":"2019","issue":null,"author":"Gallan","volume":"74","first-page":"853","unstructured":null,"article-title":"Renal vasculitis and pauci-immune glomerulonephritis associated with immune checkpoint inhibitors","journal-title":"Am J Kidney Dis","doi-asserted-by":"crossref"},{"DOI":"10.2169/internalmedicine.9814-17","key":"10.1016/j.ekir.2026.106529_bib9","year":"2018","issue":null,"author":"Kishi","volume":"57","first-page":"1259","unstructured":null,"article-title":"IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma","journal-title":"Intern Med","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S2468024926027610"],"article-number":"106529","content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,6]]},"reference-count":9,"published-online":null,"references-count":9,"short-container-title":["Kidney International Reports"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1016/j.ekir.2026.106529","is_oa":true,"title":"Single-Center Perspective of Glomerular Pathology in Patients Treated with Checkpoint Inhibitors","updated":"2026-05-12T08:54:10+00:00","published_date":"2026-04-06","best_oa_location":{"url":"https://doi.org/10.1016/j.ekir.2026.106529","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1016/j.ekir.2026.106529"}}},"created_at":"2026-05-13T13:19:23.021Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"brand","value":"Keytruda","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"brand","value":"Opdivo","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"brand","value":"Soliris","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"brand","value":"Tecentriq","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"brand","value":"Ultomiris","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"brand","value":"Yervoy","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"category","value":"Urology & Nephrology","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"condition","value":"IgA Nephropathy","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"condition","value":"Immune Checkpoint Inhibitor-Associated Nephrotoxicity","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"condition","value":"Membranous Nephropathy","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"condition","value":"Pauci-Immune Glomerulonephritis","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"condition","value":"Thrombotic Microangiopathy","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"generic","value":"atezolizumab","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"generic","value":"bevacizumab","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"generic","value":"eculizumab","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"generic","value":"ipilimumab","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"generic","value":"nivolumab","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"generic","value":"pembrolizumab","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"generic","value":"ravulizumab","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"generic","value":"rituximab","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"modality","value":"Complement Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"modality","value":"Immune Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"modality","value":"VEGF Pathway Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"sample_size","value":"n=28","value_numeric":28},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"warning","value":"Complement activation was tested in TMA cases but methodology is not fully detailed; eculizumab benefit was observed in only one case with confirmed terminal complement activation.","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"warning","value":"The 13% glomerular pathology rate applies only to biopsied patients — true incidence among all ICI-treated patients cannot be calculated from this study.","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"warning","value":"The cohort is small (n=28); findings, especially rechallenge recurrence rate (3/7), should be interpreted cautiously given wide uncertainty around estimates.","value_numeric":null},{"paper_doi":"10.1016/j.ekir.2026.106529","tag_type":"warning","value":"The 'practice_changing' impact flag reflects the study's emphasis that biopsy-guided distinction of TMA vs. immune GN directly alters management (immunosuppression vs. drug withdrawal), though evidence remains limited by study size.","value_numeric":null}],"summaries":{"what_studied":"This 11-year (2014–2025) single-center retrospective cohort evaluated biopsy-proven glomerular disease in 28 patients who received immune checkpoint inhibitors (ICIs), characterizing lesion types, clinical course, management, and outcomes.","key_result":"TMA was the most common lesion (15/28, 54%), present exclusively in patients co-exposed to VEGF-pathway inhibitors or gemcitabine. Non-TMA lesions (13/28) were diverse; IgA nephropathy was most frequent (21% of all cases). Complete renal recovery occurred in 42% (11/26 evaluable); 15% progressed to dialysis dependence. ICI rechallenge led to recurrent AKI in 43% (3/7). Overall 1-year mortality was 61%, driven by cancer progression.","limitations":"- Small sample (n=28), retrospective, single-center design with selection bias toward severe/atypical presentations requiring biopsy.\n- No at-risk denominator — the 13% glomerular rate reflects the biopsy cohort, not all ICI-treated patients.\n- Variable follow-up with limited long-term outcome data.","practice_takeaway":"Kidney biopsy is essential in ICI patients with renal injury: TMA often reflects concurrent VEGF-pathway or gemcitabine exposure rather than immune dysregulation and should prompt drug withdrawal rather than immunosuppression. ICI rechallenge carries a ~43% risk of recurrent AKI and warrants multidisciplinary assessment with close monitoring."}},{"doi":"10.1038/s41575-026-01209-5","pmid":"42092171","title":"Cirrhosis, portal hypertension and hepatocellular carcinoma: a stage-based approach","journal_title":"Nature Reviews Gastroenterology & Hepatology","journal_issn":"1759-5045","published_at":"2026-05-07T00:00:00.000Z","url":"https://doi.org/10.1038/s41575-026-01209-5","source_score":42,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-05-10","doi":"10.1038/s41575-026-01209-5","days":"7","issn":"1759-5045","rank":"1","field":"Clinical Medicine","score":"42","category":"Gastroenterology & Hepatology","categories":["Gastroenterology & Hepatology"],"_categories":["Gastroenterology & Hepatology"]},"pubmed":{"doi":"10.1038/s41575-026-01209-5","title":"Cirrhosis, portal hypertension and hepatocellular carcinoma: a stage-based approach.","journal":"Nature reviews. Gastroenterology & hepatology","methods":"","results":"","abstract":"$30","keywords":[],"pubmed_id":"42092171","conclusions":"","publication_date":"2026-05-07T00:00:00"},"crossref":{"DOI":"10.1038/s41575-026-01209-5","URL":"https://doi.org/10.1038/s41575-026-01209-5","ISSN":["1759-5045","1759-5053"],"link":[{"URL":"https://www.nature.com/articles/s41575-026-01209-5.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://www.nature.com/articles/s41575-026-01209-5","content-type":"text/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https://www.nature.com/articles/s41575-026-01209-5.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Cirrhosis, portal hypertension and hepatocellular carcinoma: a stage-based approach"],"author":[{"given":"Manon","family":"Allaire","sequence":"first","affiliation":[]},{"given":"Tamar","family":"Taddei","sequence":"additional","affiliation":[]},{"given":"Dominique","family":"Thabut","sequence":"additional","affiliation":[]},{"given":"Guadalupe","family":"Garcia-Tsao","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2026,5,6]]},"member":"297","prefix":"10.1038","source":"Crossref","volume":null,"created":{"date-time":"2026-05-06T13:14:39Z","timestamp":1778073279000,"date-parts":[[2026,5,6]]},"indexed":{"date-time":"2026-05-06T20:16:31Z","timestamp":1778098591889,"date-parts":[[2026,5,6]]},"license":[{"URL":"https://www.springernature.com/gp/researchers/text-and-data-mining","start":{"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000,"date-parts":[[2026,5,6]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.springernature.com/gp/researchers/text-and-data-mining","start":{"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000,"date-parts":[[2026,5,6]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://www.nature.com/articles/s41575-026-01209-5"}},"subtitle":[],"assertion":[{"name":"accepted","group":{"name":"ArticleHistory","label":"Article History"},"label":"Accepted","order":1,"value":"7 April 2026"},{"name":"first_online","group":{"name":"ArticleHistory","label":"Article History"},"label":"First Online","order":2,"value":"6 May 2026"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"},"order":1,"value":"M.A. reports receiving consulting fees from AstraZeneca and Roche, and speaker honoraria from AstraZeneca, Bayer, AbbVie, Gilead, Roche and Sirtex. The other authors declare no competing interests."}],"deposited":{"date-time":"2026-05-06T20:02:16Z","timestamp":1778097736000,"date-parts":[[2026,5,6]]},"issn-type":[{"type":"print","value":"1759-5045"},{"type":"electronic","value":"1759-5053"}],"published":{"date-parts":[[2026,5,6]]},"publisher":"Springer Science and Business Media LLC","reference":[{"DOI":"10.1016/j.jhep.2021.12.022","key":"1209_CR1","year":"2022","issue":null,"author":"R de Franchis","volume":"76","first-page":"959","unstructured":"de Franchis, R. et al. Baveno VII – renewing consensus in portal hypertension. J. Hepatol. 76, 959–974 (2022).","article-title":null,"journal-title":"J. Hepatol.","doi-asserted-by":"publisher"},{"DOI":"10.1097/HEP.0000000000000647","key":"1209_CR2","year":"2024","issue":null,"author":"DE Kaplan","volume":"79","first-page":"1180","unstructured":"Kaplan, D. E. et al. AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 79, 1180–1211 (2024).","article-title":null,"journal-title":"Hepatology","doi-asserted-by":"publisher"},{"DOI":"10.1053/j.gastro.2007.05.024","key":"1209_CR3","year":"2007","issue":null,"author":"C Ripoll","volume":"133","first-page":"481","unstructured":"Ripoll, C. et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 133, 481–488 (2007).","article-title":null,"journal-title":"Gastroenterology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jhep.2024.05.033","key":"1209_CR4","year":"2024","issue":null,"author":"R Paternostro","volume":"81","first-page":"827","unstructured":"Paternostro, R. et al. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD. J. Hepatol. 81, 827–836 (2024).","article-title":null,"journal-title":"J. Hepatol.","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10620-006-9310-2","key":"1209_CR5","year":"2006","issue":null,"author":"M Wadhawan","volume":"51","first-page":"2264","unstructured":"Wadhawan, M., Dubey, S., Sharma, B. C. & Sarin, S. K. Hepatic venous pressure gradient in cirrhosis: correlation with the size of varices, bleeding, ascites, and Child’s status. Dig. Dis. Sci. 51, 2264–2269 (2006).","article-title":null,"journal-title":"Dig. Dis. Sci.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jhep.2022.05.021","key":"1209_CR6","year":"2022","issue":null,"author":"C Villanueva","volume":"77","first-page":"1014","unstructured":"Villanueva, C. et al. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. J. Hepatol. 77, 1014–1025 (2022).","article-title":null,"journal-title":"J. Hepatol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(18)31875-0","key":"1209_CR7","year":"2019","issue":null,"author":"C Villanueva","volume":"393","first-page":"1597","unstructured":"Villanueva, C. et al. β-Blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 393, 1597–1608 (2019).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jhep.2024.08.028","key":"1209_CR8","year":"2025","issue":null,"author":"B Sangro","volume":"82","first-page":"315","unstructured":"Sangro, B. et al. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J. Hepatol. 82, 315–374 (2025).","article-title":null,"journal-title":"J. Hepatol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jhep.2025.10.020","key":"1209_CR9","year":"2026","issue":null,"author":"M Reig","volume":"84","first-page":"631","unstructured":"Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update. J. Hepatol. 84, 631–654 (2026).","article-title":null,"journal-title":"J. Hepatol.","doi-asserted-by":"publisher"},{"DOI":"10.1002/hep.31309","key":"1209_CR10","year":"2021","issue":null,"author":"E Wolf","volume":"73","first-page":"713","unstructured":"Wolf, E., Rich, N. E., Marrero, J. A., Parikh, N. D. & Singal, A. G. Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis. Hepatology 73, 713–725 (2021).","article-title":null,"journal-title":"Hepatology","doi-asserted-by":"publisher"},{"DOI":"10.1097/HEP.0000000000000466","key":"1209_CR11","year":"2023","issue":null,"author":"AG Singal","volume":null,"first-page":null,"unstructured":"Singal, A. G. et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology https://doi.org/10.1097/HEP.0000000000000466 (2023).","article-title":null,"journal-title":"Hepatology","doi-asserted-by":"publisher"},{"DOI":"10.1002/hep.27864","key":"1209_CR12","year":"2015","issue":null,"author":"F Faitot","volume":"62","first-page":"179","unstructured":"Faitot, F. et al. Impact of clinically evident portal hypertension on the course of hepatocellular carcinoma in patients listed for liver transplantation. Hepatology 62, 179–187 (2015).","article-title":null,"journal-title":"Hepatology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.dld.2018.07.014","key":"1209_CR13","year":"2019","issue":null,"author":"M Allaire","volume":"51","first-page":"86","unstructured":"Allaire, M. et al. Virologic control and severity of liver disease determine survival after radiofrequency ablation of hepatocellular carcinoma on cirrhosis. Dig. Liver Dis. 51, 86–94 (2019).","article-title":null,"journal-title":"Dig. Liver Dis.","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00330-017-5145-9","key":"1209_CR14","year":"2018","issue":null,"author":"JW Choi","volume":"28","first-page":"2184","unstructured":"Choi, J. W. et al. Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma. Eur. Radiol. 28, 2184–2193 (2018).","article-title":null,"journal-title":"Eur. Radiol.","doi-asserted-by":"publisher"},{"DOI":null,"key":"1209_CR15","year":"2022","issue":null,"author":"L Müller","volume":"10","first-page":"41","unstructured":"Müller, L. et al. Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. United Eur. Gastroenterol. J. 10, 41–53 (2022).","article-title":null,"journal-title":"Gastroenterol. J.","doi-asserted-by":null},{"DOI":"10.1111/liv.70337","key":"1209_CR16","year":"2025","issue":null,"author":"M Allaire","volume":"45","first-page":null,"unstructured":"Allaire, M. et al. Real-world outcomes of atezolizumab–bevacizumab in hepatocellular carcinoma: the prospective French CHIEF cohort. Liver Int. 45, e70337 (2025).","article-title":null,"journal-title":"Liver Int.","doi-asserted-by":"publisher"},{"DOI":"10.1002/hep.32468","key":"1209_CR17","year":"2022","issue":null,"author":"A D’Alessio","volume":"76","first-page":"1000","unstructured":"D’Alessio, A. et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child–Pugh A and B cirrhosis: a real-world study. Hepatology 76, 1000–1012 (2022).","article-title":null,"journal-title":"Hepatology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jhep.2009.01.014","key":"1209_CR18","year":"2009","issue":null,"author":"C Ripoll","volume":"50","first-page":"923","unstructured":"Ripoll, C. et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J. Hepatol. 50, 923–928 (2009).","article-title":null,"journal-title":"J. Hepatol.","doi-asserted-by":"publisher"},{"DOI":null,"key":"1209_CR19","year":"2010","issue":null,"author":"X Liao","volume":"24","first-page":"1669","unstructured":"Liao, X. et al. The β-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor κB signaling. Oncol. Rep. 24, 1669–1676 (2010).","article-title":null,"journal-title":"Oncol. Rep.","doi-asserted-by":null},{"DOI":"10.1097/CAD.0b013e32832bd1e3","key":"1209_CR20","year":"2009","issue":null,"author":"HA Al-Wadei","volume":"20","first-page":"477","unstructured":"Al-Wadei, H. A., Al-Wadei, M. H. & Schuller, H. M. Prevention of pancreatic cancer by the beta-blocker propranolol. Anticancer. Drugs 20, 477–482 (2009).","article-title":null,"journal-title":"Anticancer. Drugs","doi-asserted-by":"publisher"},{"DOI":"10.1002/hep.510310109","key":"1209_CR21","year":"2000","issue":null,"author":"M Pérez-Páramo","volume":"31","first-page":"43","unstructured":"Pérez-Páramo, M. et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 31, 43–48 (2000).","article-title":null,"journal-title":"Hepatology","doi-asserted-by":"publisher"},{"DOI":"10.1111/liv.12782","key":"1209_CR22","year":"2015","issue":null,"author":"M Thiele","volume":"35","first-page":"2009","unstructured":"Thiele, M. et al. Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials. Liver Int. 35, 2009–2016 (2015).","article-title":null,"journal-title":"Liver Int.","doi-asserted-by":"publisher"},{"DOI":"10.1053/j.gastro.2009.01.043","key":"1209_CR23","year":"2009","issue":null,"author":"JG Abraldes","volume":"136","first-page":"1651","unstructured":"Abraldes, J. G. et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136, 1651–1658 (2009).","article-title":null,"journal-title":"Gastroenterology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.dld.2015.07.156","key":"1209_CR24","year":"2015","issue":null,"author":"P Pollo-Flores","volume":"47","first-page":"957","unstructured":"Pollo-Flores, P. et al. Three months of simvastatin therapy vs placebo for severe portal hypertension in cirrhosis: a randomized controlled trial. Dig. Liver Dis. 47, 957–963 (2015).","article-title":null,"journal-title":"Dig. Liver Dis.","doi-asserted-by":"publisher"},{"DOI":"10.5493/wjem.v14.i4.98543","key":"1209_CR25","year":"2024","issue":null,"author":"ZI Tarar","volume":"14","first-page":null,"unstructured":"Tarar, Z. I. et al. Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. World J. Exp. Med. 14, 98543 (2024).","article-title":null,"journal-title":"World J. Exp. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1155/2022/5389044","key":"1209_CR26","year":"2022","issue":null,"author":"Y Wang","volume":"2022","first-page":null,"unstructured":"Wang, Y. et al. A meta-analysis of statin use and risk of hepatocellular carcinoma. Can. J. Gastroenterol. Hepatol. 2022, 5389044 (2022).","article-title":null,"journal-title":"Can. J. Gastroenterol. Hepatol.","doi-asserted-by":"publisher"},{"DOI":"10.1002/hep4.1640","key":"1209_CR27","year":"2021","issue":null,"author":"ZN Memel","volume":"5","first-page":"133","unstructured":"Memel, Z. N. et al. Aspirin use is associated with a reduced incidence of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol. Commun. 5, 133–143 (2021).","article-title":null,"journal-title":"Hepatol. Commun.","doi-asserted-by":"publisher"},{"DOI":"10.1111/liv.14977","key":"1209_CR28","year":"2021","issue":null,"author":"M Allaire","volume":"41","first-page":"1734","unstructured":"Allaire, M., Rudler, M. & Thabut, D. Portal hypertension and hepatocellular carcinoma: des liaisons dangereuses…. Liver Int. 41, 1734–1743 (2021).","article-title":null,"journal-title":"Liver Int.","doi-asserted-by":"publisher"},{"DOI":"10.1097/SLA.0000000000006185","key":"1209_CR29","year":"2024","issue":null,"author":"D Aliseda","volume":"280","first-page":"46","unstructured":"Aliseda, D. et al. The impact of portal hypertension assessment method on the outcomes of hepatocellular carcinoma resection: a meta-analysis of matched cohort and prospective studies. Ann. Surg. 280, 46–55 (2024).","article-title":null,"journal-title":"Ann. Surg.","doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pone.0190512","key":"1209_CR30","year":"2018","issue":null,"author":"Z Huang","volume":"13","first-page":null,"unstructured":"Huang, Z. et al. Prognostic value of liver stiffness measurement for the liver-related surgical outcomes of patients under hepatic resection: a meta-analysis. PLoS ONE 13, e0190512 (2018).","article-title":null,"journal-title":"PLoS ONE","doi-asserted-by":"publisher"},{"DOI":"10.3390/cancers11071022","key":"1209_CR31","year":"2019","issue":null,"author":"N Pavlovic","volume":"11","first-page":null,"unstructured":"Pavlovic, N., Rani, B., Gerwins, P. & Heindryckx, F. Platelets as key factors in hepatocellular carcinoma. Cancers 11, 1022 (2019).","article-title":null,"journal-title":"Cancers","doi-asserted-by":"publisher"},{"DOI":"10.3390/cancers11101568","key":"1209_CR32","year":"2019","issue":null,"author":"Q Lai","volume":"11","first-page":null,"unstructured":"Lai, Q. et al. Platelets and hepatocellular cancer: bridging the bench to the clinics. Cancers 11, 1568 (2019).","article-title":null,"journal-title":"Cancers","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jhep.2011.06.027","key":"1209_CR33","year":"2012","issue":null,"author":"E Llop","volume":"56","first-page":"103","unstructured":"Llop, E. et al. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J. Hepatol. 56, 103–108 (2012).","article-title":null,"journal-title":"J. Hepatol.","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12072-017-9799-9","key":"1209_CR34","year":"2017","issue":null,"author":"M Omata","volume":"11","first-page":"317","unstructured":"Omata, M. et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol. Int. 11, 317–370 (2017).","article-title":null,"journal-title":"Hepatol. Int.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jhep.2013.04.009","key":"1209_CR35","year":"2013","issue":null,"author":"A Cucchetti","volume":"59","first-page":"300","unstructured":"Cucchetti, A. et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J. Hepatol. 59, 300–307 (2013).","article-title":null,"journal-title":"J. Hepatol.","doi-asserted-by":"publisher"},{"DOI":"10.1159/000521665","key":"1209_CR36","year":"2022","issue":null,"author":"T Takayama","volume":"11","first-page":"209","unstructured":"Takayama, T. et al. Surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF trial). Liver Cancer 11, 209–218 (2022).","article-title":null,"journal-title":"Liver Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jhep.2018.12.027","key":"1209_CR37","year":"2019","issue":null,"author":"A Doyle","volume":"70","first-page":"866","unstructured":"Doyle, A. et al. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. J. Hepatol. 70, 866–873 (2019).","article-title":null,"journal-title":"J. Hepatol.","doi-asserted-by":"publisher"},{"DOI":"10.1002/hep.27431","key":"1209_CR38","year":"2015","issue":null,"author":"A Berzigotti","volume":"61","first-page":"526","unstructured":"Berzigotti, A. et al. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology 61, 526–536 (2015).","article-title":null,"journal-title":"Hepatology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jhepr.2020.100190","key":"1209_CR39","year":"2021","issue":null,"author":"D Azoulay","volume":"3","first-page":null,"unstructured":"Azoulay, D. et al. Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension. JHEP Rep. 3, 100190 (2021).","article-title":null,"journal-title":"JHEP Rep.","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamasurg.2016.1121","key":"1209_CR40","year":"2016","issue":null,"author":"D Citterio","volume":"151","first-page":"846","unstructured":"Citterio, D. et al. Hierarchic interaction of factors associated with liver decompensation after resection for hepatocellular carcinoma. JAMA Surg. 151, 846–853 (2016).","article-title":null,"journal-title":"JAMA Surg.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jhep.2011.12.001","key":"1209_CR41","year":"2012","issue":null,"author":"European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer","volume":"56","first-page":"908","unstructured":"European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908–943 (2012).","article-title":null,"journal-title":"J. Hepatol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jhep.2025.01.029","key":"1209_CR42","year":"2025","issue":null,"author":"European Association for the Study of the Liver","volume":"83","first-page":"177","unstructured":"European Association for the Study of the Liver EASL clinical practice guidelines on TIPS. J. Hepatol. 83, 177–210 (2025).","article-title":null,"journal-title":"J. Hepatol.","doi-asserted-by":"publisher"},{"DOI":"10.1002/ueg2.12454","key":"1209_CR43","year":"2023","issue":null,"author":"B Norero","volume":"11","first-page":"733","unstructured":"Norero, B. et al. Transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma: a systematic review. United European Gastroenterol. J. 11, 733–744 (2023).","article-title":null,"journal-title":"United European Gastroenterol. J.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clinre.2021.101790","key":"1209_CR44","year":"2021","issue":null,"author":"E Larrey","volume":"46","first-page":null,"unstructured":"Larrey, E. et al. TIPS for patients with early HCC: a bridge to liver transplantation. Clin. Res. Hepatol. Gastroenterol. 46, 101790 (2021).","article-title":null,"journal-title":"Clin. Res. Hepatol. Gastroenterol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/0016-5085(90)90296-D","key":"1209_CR45","year":"1990","issue":null,"author":"D Franco","volume":"98","first-page":"733","unstructured":"Franco, D. et al. Resection of hepatocellular carcinomas. Results in 72 European patients with cirrhosis. Gastroenterology 98, 733–738 (1990).","article-title":null,"journal-title":"Gastroenterology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.gassur.2005.09.008","key":"1209_CR46","year":"2005","issue":null,"author":"SH Teh","volume":"9","first-page":"1207","unstructured":"Teh, S. H. et al. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: MELD score predicts perioperative mortality. J. Gastrointest. Surg. 9, 1207–1215 (2005).","article-title":null,"journal-title":"J. Gastrointest. Surg.","doi-asserted-by":"publisher"},{"DOI":"10.1097/01.sla.0000201483.95911.08","key":"1209_CR47","year":"2006","issue":null,"author":"RA Schroeder","volume":"243","first-page":"373","unstructured":"Schroeder, R. A. et al. Predictive indices of morbidity and mortality after liver resection. Ann. Surg. 243, 373–379 (2006).","article-title":null,"journal-title":"Ann. Surg.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jhep.2019.08.032","key":"1209_CR48","year":"2020","issue":null,"author":"G Berardi","volume":"72","first-page":"75","unstructured":"Berardi, G. et al. Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child–Pugh B cirrhosis. J. Hepatol. 72, 75–84 (2020).","article-title":null,"journal-title":"J. Hepatol.","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00464-022-09677-x","key":"1209_CR49","year":"2023","issue":null,"author":"Y Watanabe","volume":"37","first-page":"1316","unstructured":"Watanabe, Y. et al. Influence of Child–Pugh B7 and B8/9 cirrhosis on laparoscopic liver resection for hepatocellular carcinoma: a retrospective cohort study. Surg. Endosc. 37, 1316–1333 (2023).","article-title":null,"journal-title":"Surg. Endosc.","doi-asserted-by":"publisher"},{"DOI":null,"key":"1209_CR50","year":"2015","issue":null,"author":"N Brytska","volume":"4","first-page":"373","unstructured":"Brytska, N. et al. Laparoscopic liver resection for hepatitis B and C virus-related hepatocellular carcinoma in patients with Child B or C cirrhosis. Hepatobiliary Surg. Nutr. 4, 373–378 (2015).","article-title":null,"journal-title":"Hepatobiliary Surg. Nutr.","doi-asserted-by":null},{"DOI":"10.1002/hep.26629","key":"1209_CR51","year":"2013","issue":null,"author":"C Ripoll","volume":"58","first-page":"2079","unstructured":"Ripoll, C. et al. Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma: a multicenter case-control study. Hepatology 58, 2079–2088 (2013).","article-title":null,"journal-title":"Hepatology","doi-asserted-by":"publisher"},{"DOI":"10.1053/j.gastro.2020.09.026","key":"1209_CR52","year":"2021","issue":null,"author":"O Nicoară-Farcău","volume":"160","first-page":"193","unstructured":"Nicoară-Farcău, O. et al. Effects of early placement of transjugular portosystemic shunts in patients with high-risk acute variceal bleeding: a meta-analysis of individual patient data. Gastroenterology 160, 193–205.e10 (2021).","article-title":null,"journal-title":"Gastroenterology","doi-asserted-by":"publisher"},{"DOI":"10.1002/hep.31913","key":"1209_CR53","year":"2021","issue":null,"author":"A Walter","volume":"74","first-page":"2085","unstructured":"Walter, A. et al. Combination of MELD and lactate predicts death in patients treated with salvage TIPS for refractory variceal bleeding. Hepatology 74, 2085–2101 (2021).","article-title":null,"journal-title":"Hepatology","doi-asserted-by":"publisher"},{"DOI":"10.3389/ti.2024.12781","key":"1209_CR54","year":"2024","issue":null,"author":"S El Hajji","volume":"37","first-page":null,"unstructured":"El Hajji, S. et al. Transjugular intrahepatic portosystemic shunt is associated with better waitlist management of liver transplant candidates with hepatocellular carcinoma. Transpl. Int. 37, 12781 (2024).","article-title":null,"journal-title":"Transpl. Int.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.tranon.2020.100864","key":"1209_CR55","year":"2020","issue":null,"author":"H Yan","volume":"13","first-page":null,"unstructured":"Yan, H. et al. Feasibility and clinical value of TIPS combined with subsequent antitumor treatment in HCC patients with refractory ascites. Transl. Oncol. 13, 100864 (2020).","article-title":null,"journal-title":"Transl. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1111/apt.17599","key":"1209_CR56","year":"2023","issue":null,"author":"M Allaire","volume":"58","first-page":"346","unstructured":"Allaire, M. et al. Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinoma. Aliment. Pharmacol. Ther. 58, 346–356 (2023).","article-title":null,"journal-title":"Aliment. Pharmacol. Ther.","doi-asserted-by":"publisher"},{"DOI":"10.1111/jgh.16218","key":"1209_CR57","year":"2023","issue":null,"author":"CWK Wu","volume":"38","first-page":"1381","unstructured":"Wu, C. W. K. et al. Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different Barcelona Clinic liver cancer stages. J. Gastroenterol. Hepatol. 38, 1381–1388 (2023).","article-title":null,"journal-title":"J. Gastroenterol. Hepatol.","doi-asserted-by":"publisher"},{"DOI":"10.3390/cancers15092480","key":"1209_CR58","year":"2023","issue":null,"author":"CWK Wu","volume":"15","first-page":null,"unstructured":"Wu, C. W. K. et al. Baveno VII criteria is an accurate risk stratification tool to predict high-risk varices requiring intervention and hepatic events in patients with advanced hepatocellular carcinoma. Cancers 15, 2480 (2023).","article-title":null,"journal-title":"Cancers","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jhep.2015.05.022","key":"1209_CR59","year":"2015","issue":null,"author":"R de Franchis","volume":"63","first-page":"743","unstructured":"de Franchis, R. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J. Hepatol. 63, 743–752 (2015).","article-title":null,"journal-title":"J. Hepatol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clinre.2022.102059","key":"1209_CR60","year":"2023","issue":null,"author":"M Allaire","volume":"47","first-page":null,"unstructured":"Allaire, M. et al. Screening and management of portal hypertension in advanced hepatocellular carcinoma: a French practice survey. Clin. Res. Hepatol. Gastroenterol. 47, 102059 (2023).","article-title":null,"journal-title":"Clin. Res. Hepatol. Gastroenterol.","doi-asserted-by":"publisher"},{"DOI":"10.1002/hep.29883","key":"1209_CR61","year":"2018","issue":null,"author":"MH Hyun","volume":"68","first-page":"977","unstructured":"Hyun, M. H. et al. Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: a meta-analysis of high-quality studies. Hepatology 68, 977–993 (2018).","article-title":null,"journal-title":"Hepatology","doi-asserted-by":"publisher"},{"DOI":"10.7314/APJCP.2015.16.13.5541","key":"1209_CR62","year":"2015","issue":null,"author":"XD Yang","volume":"16","first-page":"5541","unstructured":"Yang, X. D. et al. Systematic review of single large and/or multinodular hepatocellular carcinoma: surgical resection improves survival. Asian Pac. J. Cancer Prev. 16, 5541–5547 (2015).","article-title":null,"journal-title":"Asian Pac. J. Cancer Prev.","doi-asserted-by":"publisher"},{"DOI":"10.1002/bjs.8915","key":"1209_CR63","year":"2012","issue":null,"author":"KC Lim","volume":"99","first-page":"1622","unstructured":"Lim, K. C. et al. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br. J. Surg. 99, 1622–1629 (2012).","article-title":null,"journal-title":"Br. J. Surg.","doi-asserted-by":"publisher"},{"DOI":"10.7150/jca.50371","key":"1209_CR64","year":"2021","issue":null,"author":"Y Huang","volume":"12","first-page":"1770","unstructured":"Huang, Y. et al. Preoperative portal vein embolization for liver resection: an updated meta-analysis. J. Cancer 12, 1770–1778 (2021).","article-title":null,"journal-title":"J. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1002/hep.31819","key":"1209_CR65","year":"2021","issue":null,"author":"R Salem","volume":"74","first-page":"2342","unstructured":"Salem, R. et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology 74, 2342–2352 (2021).","article-title":null,"journal-title":"Hepatology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jvir.2018.06.027","key":"1209_CR66","year":"2018","issue":null,"author":"A Gabr","volume":"29","first-page":"1502","unstructured":"Gabr, A. et al. Outcomes of surgical resection after radioembolization for hepatocellular carcinoma. J. Vasc. Interv. Radiol. 29, 1502–1510.e1 (2018).","article-title":null,"journal-title":"J. Vasc. Interv. Radiol.","doi-asserted-by":"publisher"},{"DOI":"10.1007/s11605-021-05095-x","key":"1209_CR67","year":"2021","issue":null,"author":"M Qadan","volume":"25","first-page":"2690","unstructured":"Qadan, M. et al. Review of use of Y90 as a bridge to liver resection and transplantation in hepatocellular carcinoma. J. Gastrointest. Surg. 25, 2690–2699 (2021).","article-title":null,"journal-title":"J. Gastrointest. Surg.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jhep.2020.09.026","key":"1209_CR68","year":"2021","issue":null,"author":"TH Kim","volume":"74","first-page":"603","unstructured":"Kim, T. H. et al. Proton beam radiotherapy vs radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial. J. Hepatol. 74, 603–612 (2021).","article-title":null,"journal-title":"J. Hepatol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ejca.2020.04.024","key":"1209_CR69","year":"2020","issue":null,"author":"AS Mathew","volume":"134","first-page":"41","unstructured":"Mathew, A. S. et al. Long-term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. Eur. J. Cancer 134, 41–51 (2020).","article-title":null,"journal-title":"Eur. J. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.annonc.2024.08.2279","key":"1209_CR70","year":"2024","issue":null,"author":"A Yopp","volume":"35","first-page":"S1230","unstructured":"Yopp, A. et al. Updated efficacy and safety data from IMbrave050: phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC) [abstract LBA39]. Ann. Oncol. 35, S1230 (2024).","article-title":null,"journal-title":"Ann. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1002/ueg2.12488","key":"1209_CR71","year":"2023","issue":null,"author":"H Giudicelli","volume":"11","first-page":"985","unstructured":"Giudicelli, H. et al. Portal-hypertension features are associated with ascites occurrence and survival in patients with hepatocellular carcinoma treated by external radiotherapy. United European Gastroenterol. J. 11, 985–997 (2023).","article-title":null,"journal-title":"United European Gastroenterol. J.","doi-asserted-by":"publisher"},{"DOI":"10.1136/gutjnl-2023-330419","key":"1209_CR72","year":"2023","issue":null,"author":"TC Yang","volume":"73","first-page":"682","unstructured":"Yang, T. C. et al. Endoscopic variceal ligation versus propranolol for the primary prevention of oesophageal variceal bleeding in patients with hepatocellular carcinoma: an open-label, two-centre, randomised controlled trial. Gut 73, 682–690 (2023).","article-title":null,"journal-title":"Gut","doi-asserted-by":"publisher"},{"DOI":"10.1136/gutjnl-2023-331181","key":"1209_CR73","year":"2024","issue":null,"author":"HV Tevethia","volume":"73","first-page":"1844","unstructured":"Tevethia, H. V. et al. Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child–Turcotte–Pugh B and C cirrhosis with high-risk oesophageal varices: the CAVARLY trial. Gut 73, 1844–1853 (2024).","article-title":null,"journal-title":"Gut","doi-asserted-by":"publisher"},{"DOI":"10.1177/2050640619840199","key":"1209_CR74","year":"2019","issue":null,"author":"B Scheiner","volume":"7","first-page":"850","unstructured":"Scheiner, B. et al. Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. United European Gastroenterol. J. 7, 850–858 (2019).","article-title":null,"journal-title":"United European Gastroenterol. J.","doi-asserted-by":"publisher"},{"DOI":"10.1159/000529173","key":"1209_CR75","year":"2023","issue":null,"author":"A Vogel","volume":"12","first-page":"372","unstructured":"Vogel, A. et al. Predictive and prognostic potential of liver function assessment in patients with advanced hepatocellular carcinoma: a systematic literature review. Liver Cancer 12, 372–391 (2023).","article-title":null,"journal-title":"Liver Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1159/000480256","key":"1209_CR76","year":"2017","issue":null,"author":"A Hiraoka","volume":"35","first-page":"602","unstructured":"Hiraoka, A. et al. Hepatic function during repeated TACE procedures and prognosis after introducing sorafenib in patients with unresectable hepatocellular carcinoma: multicenter analysis. Dig. Dis. 35, 602–610 (2017).","article-title":null,"journal-title":"Dig. Dis.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(24)02551-0","key":"1209_CR77","year":"2025","issue":null,"author":"B Sangro","volume":"405","first-page":"216","unstructured":"Sangro, B. et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet 405, 216–232 (2025).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(24)02575-3","key":"1209_CR78","year":"2025","issue":null,"author":"M Kudo","volume":"405","first-page":"203","unstructured":"Kudo, M. et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet 405, 203–215 (2025).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1136/jitc-2022-005457","key":"1209_CR79","year":"2022","issue":null,"author":"M de la Torre-Aláez","volume":"10","first-page":null,"unstructured":"de la Torre-Aláez, M. et al. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. J. Immunother. Cancer 10, e005457 (2022).","article-title":null,"journal-title":"J. Immunother. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2024.42.3_suppl.LBA432","key":"1209_CR80","year":"2024","issue":"3_suppl.","author":"R Lencioni","volume":"42","first-page":"LBA432","unstructured":"Lencioni, R. et al. EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in unresectable HCC eligible for embolization [abstract]. J. Clin. Oncol. 42 (Suppl. 3), LBA432 (2024).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1097/MEG.0b013e32834701f5","key":"1209_CR81","year":"2011","issue":null,"author":"C Elia","volume":"23","first-page":"573","unstructured":"Elia, C. et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in cirrhosis: influence on portal hypertension. Eur. J. Gastroenterol. Hepatol. 23, 573–577 (2011).","article-title":null,"journal-title":"Eur. J. Gastroenterol. Hepatol.","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10620-007-0148-z","key":"1209_CR82","year":"2008","issue":null,"author":"TF Jakobs","volume":"53","first-page":"2556","unstructured":"Jakobs, T. F. et al. Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres. Dig. Dis. Sci. 53, 2556–2563 (2008).","article-title":null,"journal-title":"Dig. Dis. Sci.","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa0708857","key":"1209_CR83","year":"2008","issue":null,"author":"JM Llovet","volume":"359","first-page":"378","unstructured":"Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1717002","key":"1209_CR84","year":"2018","issue":null,"author":"GK Abou-Alfa","volume":"379","first-page":"54","unstructured":"Abou-Alfa, G. K. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379, 54–63 (2018).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(16)32453-9","key":"1209_CR85","year":"2017","issue":null,"author":"J Bruix","volume":"389","first-page":"56","unstructured":"Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56–66 (2017).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(18)30207-1","key":"1209_CR86","year":"2018","issue":null,"author":"M Kudo","volume":"391","first-page":"1163","unstructured":"Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163–1173 (2018).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1915745","key":"1209_CR87","year":"2020","issue":null,"author":"RS Finn","volume":"382","first-page":"1894","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jhep.2021.11.030","key":"1209_CR88","year":"2022","issue":null,"author":"AL Cheng","volume":"76","first-page":"862","unstructured":"Cheng, A. L. et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Hepatol. 76, 862–873 (2022).","article-title":null,"journal-title":"J. Hepatol.","doi-asserted-by":"publisher"},{"DOI":"10.1056/EVIDoa2100070","key":"1209_CR89","year":"2022","issue":null,"author":"GK Abou-Alfa","volume":"1","first-page":null,"unstructured":"Abou-Alfa, G. K. et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 1, EVIDoa2100070 (2022).","article-title":null,"journal-title":"NEJM Evid.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(21)00252-7","key":"1209_CR90","year":"2021","issue":null,"author":"Z Ren","volume":"22","first-page":"977","unstructured":"Ren, Z. et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. Lancet Oncol. 22, 977–990 (2021).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2024.42.17_suppl.LBA4008","key":"1209_CR91","year":"2024","issue":"17_suppl.","author":"PR Galle","volume":"42","first-page":"LBA4008","unstructured":"Galle, P. R. et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable HCC (uHCC): first results from CheckMate 9DW [abstract]. J. Clin. Oncol. 42 (Suppl. 17), LBA4008 (2024).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jhepr.2024.101120","key":"1209_CR92","year":"2024","issue":null,"author":"M Allaire","volume":"6","first-page":null,"unstructured":"Allaire, M., Sultanik, P. & Thabut, D. Anticoagulation is not associated with an increased risk of variceal bleeding under systemic therapy for advanced HCC. JHEP Rep. 6, 101120 (2024).","article-title":null,"journal-title":"JHEP Rep.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.dld.2024.02.018","key":"1209_CR93","year":"2024","issue":null,"author":"P Sultanik","volume":"56","first-page":"1621","unstructured":"Sultanik, P. et al. Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with atezolizumab–bevacizumab. Dig. Liver Dis. 56, 1621–1630 (2024).","article-title":null,"journal-title":"Dig. Liver Dis.","doi-asserted-by":"publisher"},{"DOI":"10.1111/liv.15458","key":"1209_CR94","year":"2022","issue":null,"author":"E Larrey","volume":"42","first-page":"2843","unstructured":"Larrey, E. et al. A history of variceal bleeding is associated with further bleeding under atezolizumab–bevacizumab in patients with HCC. Liver Int. 42, 2843–2854 (2022).","article-title":null,"journal-title":"Liver Int.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jhepr.2024.101065","key":"1209_CR95","year":"2024","issue":null,"author":"N Ben Khaled","volume":"6","first-page":null,"unstructured":"Ben Khaled, N. et al. Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: multicenter real-world study with focus on bleeding and thromboembolic events. JHEP Rep. 6, 101065 (2024).","article-title":null,"journal-title":"JHEP Rep.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jhep.2025.08.033","key":"1209_CR96","year":"2026","issue":null,"author":"M Allaire","volume":"84","first-page":"e74","unstructured":"Allaire, M. et al. A role for non-selective beta-blockers in preventing liver decompensation in patients with hepatocellular carcinoma undergoing systemic therapy. J. Hepatol. 84, e74–e76 (2026).","article-title":null,"journal-title":"J. Hepatol.","doi-asserted-by":"publisher"},{"DOI":"10.1158/1078-0432.CCR-24-2582","key":"1209_CR97","year":"2025","issue":null,"author":"G Cabibbo","volume":"31","first-page":"543","unstructured":"Cabibbo, G. et al. Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab or sorafenib at highest risk of death. Clin. Cancer Res. 31, 543–550 (2025).","article-title":null,"journal-title":"Clin. Cancer Res.","doi-asserted-by":"publisher"},{"DOI":"10.1111/liv.70092","key":"1209_CR98","year":"2025","issue":null,"author":"F Piñero","volume":"45","first-page":null,"unstructured":"Piñero, F. et al. Hepatic recompensation before systemic therapy for hepatocellular carcinoma yields comparable survival to compensated cirrhosis. Liver Int. 45, e70092 (2025).","article-title":null,"journal-title":"Liver Int.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jhep.2021.04.047","key":"1209_CR99","year":"2021","issue":null,"author":"M Kudo","volume":"75","first-page":"600","unstructured":"Kudo, M. et al. CheckMate 040 cohort 5: a phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child–Pugh B cirrhosis. J. Hepatol. 75, 600–609 (2021).","article-title":null,"journal-title":"J. Hepatol.","doi-asserted-by":"publisher"},{"DOI":"10.1097/HEP.0000000000000030","key":"1209_CR100","year":"2023","issue":null,"author":"I El Hajra","volume":"77","first-page":"1139","unstructured":"El Hajra, I. et al. Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis. Hepatology 77, 1139–1149 (2023).","article-title":null,"journal-title":"Hepatology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clinre.2023.102199","key":"1209_CR101","year":"2023","issue":null,"author":"S Chaibi","volume":"47","first-page":null,"unstructured":"Chaibi, S. et al. Albumin infusion reduces ascites occurrence in Child–Pugh B patients treated by atezolizumab–bevacizumab for advanced HCC. Clin. Res. Hepatol. Gastroenterol. 47, 102199 (2023).","article-title":null,"journal-title":"Clin. Res. Hepatol. Gastroenterol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.dld.2025.07.019","key":"1209_CR102","year":"2025","issue":null,"author":"H Bourien","volume":"57","first-page":"2011","unstructured":"Bourien, H. et al. A multicentric national phase II trial assessing tislelizumab monotherapy for hepatocellular carcinoma Child–Pugh B: the UCGI 41 HESTIA trial design and preliminary safety data. Dig. Liver Dis. 57, 2011–2015 (2025).","article-title":null,"journal-title":"Dig. Liver Dis.","doi-asserted-by":"publisher"},{"DOI":null,"key":"1209_CR103","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04829383 (2025).","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"update-policy":"https://doi.org/10.1007/springer_crossmark_policy","alternative-id":["1209"],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"original-title":[],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"reference-count":103,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,5,6]]},"references-count":103,"short-container-title":["Nat Rev Gastroenterol Hepatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1038/s41575-026-01209-5","is_oa":false,"title":"Cirrhosis, portal hypertension and hepatocellular carcinoma: a stage-based approach","updated":"2026-05-07T14:04:23+00:00","published_date":"2026-05-06","best_oa_location":null}},"created_at":"2026-05-11T13:20:57.027Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"brand","value":"Nexavar","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"brand","value":"Tecentriq","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"condition","value":"Hepatocellular Carcinoma","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"condition","value":"Liver Cirrhosis","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"condition","value":"Portal Hypertension","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"generic","value":"atezolizumab","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"generic","value":"bevacizumab","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"generic","value":"carvedilol","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"generic","value":"propranolol","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"generic","value":"sorafenib","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"modality","value":"Immunotherapy","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"modality","value":"Non-Invasive Liver Stiffness Assessment","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"modality","value":"Non-Selective Beta-Blocker","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"modality","value":"Surgical Resection","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"modality","value":"Transarterial Chemoembolization","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"warning","value":"No sample size tag applied — this is a review article with no primary cohort.","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"warning","value":"The paper is published May 2026; some cited references (e.g., BCLC 2026 update, EASL 2025 CPGs) are very recent and may not yet be widely implemented in clinical practice.","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"warning","value":"The 'practice_changing' impact flag reflects the novelty of the proposed integrated framework, not a proven intervention tested in an RCT.","value_numeric":null},{"paper_doi":"10.1038/s41575-026-01209-5","tag_type":"warning","value":"This is a narrative review; the integrated stage-based framework is proposed but not yet validated in prospective outcome trials.","value_numeric":null}],"summaries":{"what_studied":"This narrative review proposes an integrated, stage-based framework for managing hepatocellular carcinoma (HCC) in the context of cirrhosis, using clinically significant portal hypertension (CSPH, defined as HVPG ≥10 mmHg) as a key stratifying factor across all cirrhosis stages (compensated ± CSPH, decompensated, further decompensated) and all HCC stages (very early, early, intermediate, advanced).","key_result":"Current guidelines treat portal hypertension and HCC separately, leading to suboptimal risk stratification. CSPH is associated with higher risk of cirrhosis decompensation and limits curative options like surgical resection. Emerging data support non-invasive tools (liver stiffness + platelet count) to replace HVPG and traditional surrogates (endoscopy, imaging) for CSPH assessment in HCC patients.","limitations":"- Review is based on existing literature; no new primary data are generated.\n- Non-invasive CSPH assessment tools in HCC patients are supported by 'emerging data' only and are not yet formally validated in this population.\n- Most cited HCC trials lack stratification by cirrhosis stage, limiting evidence quality for the proposed framework.","practice_takeaway":"Assess CSPH using liver stiffness and platelet count before planning curative HCC therapy, especially surgical resection — CSPH predicts decompensation risk and may rule out resection even in early-stage HCC. Future HCC clinical trials should stratify enrollment and outcomes by cirrhosis stage to generate meaningful, personalized evidence."}},{"doi":"10.1016/j.jtho.2026.103857","pmid":null,"title":"PP01.123: A Global Phase 3, Double-Blind, Randomized Trial of Pumitamig (BNT327/BMS986545; PD-L1 × VEGF-A bsAb) Plus Chemotherapy Compared to Atezolizumab Plus Chemotherapy in Patients with First-Line (1L) Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - ROSETTA Lung-01","journal_title":"Journal of Thoracic Oncology","journal_issn":"1556-0864","published_at":"2026-05-07T00:00:00.000Z","url":"https://doi.org/10.1016/j.jtho.2026.103857","source_score":8,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-05-10","doi":"10.1016/j.jtho.2026.103857","days":"7","issn":"1556-0864","rank":"1","field":"Clinical Medicine","score":"8","category":"Respiratory System","categories":["Respiratory System"],"_categories":["Respiratory System"]},"pubmed":null,"crossref":{"DOI":"10.1016/j.jtho.2026.103857","URL":"https://doi.org/10.1016/j.jtho.2026.103857","ISSN":["1556-0864"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S1556086426003102?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S1556086426003102?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"103857","type":"journal-article","issue":"5","score":1,"title":["PP01.123: A Global Phase 3, Double-Blind, Randomized Trial of Pumitamig (BNT327/BMS986545; PD-L1 × VEGF-A bsAb) Plus Chemotherapy Compared to Atezolizumab Plus Chemotherapy in Patients with First-Line (1L) Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - ROSETTA Lung-01"],"author":[{"given":"Martin","family":"Reck","sequence":"first","affiliation":[]},{"given":"John","family":"Heymach","sequence":"additional","affiliation":[]},{"given":"Kevin","family":"Franks","sequence":"additional","affiliation":[]},{"given":"Carl","family":"Gay","sequence":"additional","affiliation":[]},{"given":"Vinod","family":"Ganju","sequence":"additional","affiliation":[]},{"given":"Ina","family":"Nordman","sequence":"additional","affiliation":[]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[]},{"given":"Mehmet Ali","family":"Nahit Sendur","sequence":"additional","affiliation":[]},{"given":"Ilhan","family":"Celik","sequence":"additional","affiliation":[]},{"given":"Isaac","family":"Dai","sequence":"additional","affiliation":[]},{"given":"Secil","family":"Koseoglu","sequence":"additional","affiliation":[]},{"given":"Sarita","family":"Koride","sequence":"additional","affiliation":[]},{"given":"Karrie","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Silke","family":"Günther","sequence":"additional","affiliation":[]},{"given":"Özlem","family":"Türeci","sequence":"additional","affiliation":[]},{"given":"Ugur","family":"Sahin","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2026,5]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":"21","created":{"date-time":"2026-05-07T16:31:48Z","timestamp":1778171508000,"date-parts":[[2026,5,7]]},"indexed":{"date-time":"2026-05-07T17:13:06Z","timestamp":1778173986454,"date-parts":[[2026,5,7]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000,"date-parts":[[2026,5,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000,"date-parts":[[2026,5,1]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S1556086426003102"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"PP01.123: A Global Phase 3, Double-Blind, Randomized Trial of Pumitamig (BNT327/BMS986545; PD-L1 × VEGF-A bsAb) Plus Chemotherapy Compared to Atezolizumab Plus Chemotherapy in Patients with First-Line (1L) Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - ROSETTA Lung-01"},{"name":"journaltitle","label":"Journal Title","value":"Journal of Thoracic Oncology"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.jtho.2026.103857"},{"name":"content_type","label":"Content Type","value":"simple-article"},{"name":"copyright","label":"Copyright","value":"Copyright © 2026 Published by Elsevier Inc."}],"deposited":{"date-time":"2026-05-07T17:02:59Z","timestamp":1778173379000,"date-parts":[[2026,5,7]]},"issn-type":[{"type":"print","value":"1556-0864"}],"published":{"date-parts":[[2026,5]]},"publisher":"Elsevier BV","reference":null,"short-title":[],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S1556086426003102"],"article-number":"103857","content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,5]]},"reference-count":0,"published-online":null,"references-count":0,"special_numbering":"S1","short-container-title":["Journal of Thoracic Oncology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1016/j.jtho.2026.103857","is_oa":false,"title":"PP01.123: A Global Phase 3, Double-Blind, Randomized Trial of Pumitamig (BNT327/BMS986545; PD-L1 × VEGF-A bsAb) Plus Chemotherapy Compared to Atezolizumab Plus Chemotherapy in Patients with First-Line (1L) Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - ROSETTA Lung-01","updated":"2026-05-08T16:02:47+00:00","published_date":"2026-05-01","best_oa_location":null}},"created_at":"2026-05-11T13:20:55.270Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"brand","value":"Pumitamig","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"brand","value":"Tecentriq","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"category","value":"Respiratory System","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"condition","value":"Extensive-Stage Small Cell Lung Cancer","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"generic","value":"atezolizumab","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"generic","value":"pumitamig","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"modality","value":"Bispecific Antibody","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"modality","value":"Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"modality","value":"Chemotherapy","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"warning","value":"BNT327/BMS-986545 is listed under the brand name 'Pumitamig' per the title; this may be a non-final proprietary name as of the publication date.","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"warning","value":"Study design tag is based on the trial description in the title ('Phase 3, Double-Blind, Randomized Trial'); no protocol or results text was available to confirm.","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"warning","value":"The publisher page returned a 404 error — full text, methods, and results are entirely inaccessible. All extracted data comes solely from the paper title and metadata. No efficacy, safety, or patient-level data can be reported.","value_numeric":null}],"summaries":{"what_studied":"A global Phase 3, double-blind, randomized trial (ROSETTA Lung-01) evaluating pumitamig (BNT327/BMS-986545), a PD-L1 × VEGF-A bispecific antibody, plus chemotherapy versus atezolizumab plus chemotherapy in patients with first-line extensive-stage small cell lung cancer (ES-SCLC).","limitations":"Full text is unavailable; only the abstract title and journal metadata were accessible. No results, methods details, or patient data could be extracted."}},{"doi":"10.1016/j.lungcan.2025.108891","pmid":"41500083","title":"Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials","journal_title":"Lung Cancer","journal_issn":"0169-5002","published_at":"2026-01-08T00:00:00.000Z","url":"https://doi.org/10.1016/j.lungcan.2025.108891","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-07","doi":"10.1016/j.lungcan.2025.108891","days":"7","issn":"0169-5002","rank":"10","field":"Clinical Medicine","score":"1","category":"Respiratory System","categories":["Respiratory System"],"_categories":["Respiratory System"]},"pubmed":{"doi":"10.1016/j.lungcan.2025.108891","title":"Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials.","journal":"Lung cancer (Amsterdam, Netherlands)","methods":"","results":"Among 762 participants, 49% harbored a TP53 mutation. TP53 mutations based on binary categorization were associated with poorer but not statistically significant OS compared to wild-type (adjusted-HR 1.15; 95 %CI 0.96-1.38; P = .12). However, nonsense mutations classified by coding mutations (adjusted-HR 1.71; 95% CI 1.22-2.39;P = .002), non-missense mutations classified by Olivier's classification (adjusted-HR 1.33; 95% CI 1.03-1.74; P = .03) and disruptive mutations classified by Poeta's classification (adjusted-HR 1.33; 95% CI 1.37-1.77; P = .03) were associated with statistically significant poorer OS. TP53 status did not predict differential benefit from ICI versus chemotherapy (interaction P = .45).","abstract":"$31","keywords":["Chemotherapy","Immune checkpoint inhibitors","NSCLC","TP53"],"pubmed_id":"41500083","conclusions":"In advanced driver-negative NSCLC following progression on first-line chemotherapy, nonsense, non-missense and disruptive mutations of TP53 were strongly associated with inferior OS. These data support utilizing a nuanced classification of TP53 mutations as a stratification factor in future trials, and laboratory reporting to aid prognostication.","publication_date":"2026-01-08T00:00:00"},"crossref":{"DOI":"10.1016/j.lungcan.2025.108891","URL":"https://doi.org/10.1016/j.lungcan.2025.108891","ISSN":["0169-5002"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S0169500225007834?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S0169500225007834?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"108891","type":"journal-article","issue":null,"score":1,"title":["Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials"],"author":[{"given":"Deborah Di-Xin","family":"Zhou","sequence":"first","affiliation":[]},{"given":"Sarah J.","family":"Lord","sequence":"additional","affiliation":[]},{"given":"Frank Po-Yen","family":"Lin","sequence":"additional","affiliation":[]},{"given":"Wendy A.","family":"Cooper","sequence":"additional","affiliation":[]},{"given":"Milita","family":"Zaheed","sequence":"additional","affiliation":[]},{"given":"Robert John","family":"Simes","sequence":"additional","affiliation":[]},{"given":"Thomas","family":"John","sequence":"additional","affiliation":[]},{"given":"Chee Khoon","family":"Lee","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/501100001774","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100001774","name":"University of Sydney","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2026,2]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":"212","created":{"date-time":"2025-12-29T23:43:48Z","timestamp":1767051828000,"date-parts":[[2025,12,29]]},"indexed":{"date-time":"2026-01-06T09:31:34Z","timestamp":1767691894667,"date-parts":[[2026,1,6]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000,"date-parts":[[2026,2,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000,"date-parts":[[2026,2,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000,"date-parts":[[2025,12,29]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S0169500225007834"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials"},{"name":"journaltitle","label":"Journal Title","value":"Lung Cancer"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.lungcan.2025.108891"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2025 The Author(s). Published by Elsevier B.V."}],"deposited":{"date-time":"2026-01-06T09:26:44Z","timestamp":1767691604000,"date-parts":[[2026,1,6]]},"issn-type":[{"type":"print","value":"0169-5002"}],"published":{"date-parts":[[2026,2]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.1038/s41586-023-05729-x","key":"10.1016/j.lungcan.2025.108891_b0005","year":"2023","issue":"7957","author":"Al Bakir","volume":"616","first-page":"534","unstructured":null,"article-title":"The evolution of non-small cell lung cancer metastases in TRACERx","journal-title":"Nature","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1616288","key":"10.1016/j.lungcan.2025.108891_b0010","year":"2017","issue":"22","author":"Jamal-Hanjani","volume":"376","first-page":"2109","unstructured":null,"article-title":"Tracking the evolution of non–small-cell lung cancer","journal-title":"N. Engl. J. Med.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.celrep.2019.07.001","key":"10.1016/j.lungcan.2025.108891_b0015","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"L. A. Donehower et al., “Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas,” Cell reports, vol. 28, no. 5, pp. 1370-1384. e5, 2019.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.lungcan.2025.108891_b0020","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"TCGA Research Network. [Online]. Available: https://www.cancer.gov/tcga.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.lungcan.2025.108891_b0025","year":"2000","issue":"10","author":"Mitsudomi","volume":"6","first-page":"4055","unstructured":null,"article-title":"Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis","journal-title":"Clin. Cancer Res.","doi-asserted-by":null},{"DOI":"10.3892/mco.2016.1057","key":"10.1016/j.lungcan.2025.108891_b0030","year":"2016","issue":"6","author":"Gu","volume":"5","first-page":"705","unstructured":null,"article-title":"TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: evidence from a meta-analysis","journal-title":"Molecular and Clinical Oncology","doi-asserted-by":"crossref"},{"DOI":"10.1183/09031936.01.00062201","key":"10.1016/j.lungcan.2025.108891_b0035","year":"2001","issue":"4","author":"Steels","volume":"18","first-page":"705","unstructured":null,"article-title":"Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis","journal-title":"Eur. Respir. J.","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00432-018-2817-z","key":"10.1016/j.lungcan.2025.108891_b0040","year":"2019","issue":null,"author":"Li","volume":"145","first-page":"625","unstructured":null,"article-title":"TP53 mutations as potential prognostic markers for specific cancers: analysis of data from the Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database","journal-title":"J. Cancer Res. Clin. Oncol.","doi-asserted-by":"crossref"},{"DOI":"10.1101/gad.190678.112","key":"10.1016/j.lungcan.2025.108891_b0045","year":"2012","issue":"12","author":"Freed-Pastor","volume":"26","first-page":"1268","unstructured":null,"article-title":"Mutant p53: one name, many proteins","journal-title":"Genes Dev.","doi-asserted-by":"crossref"},{"DOI":"10.1101/cshperspect.a001016","key":"10.1016/j.lungcan.2025.108891_b0050","year":"2010","issue":"3","author":"Robles","volume":"2","first-page":null,"unstructured":null,"article-title":"Clinical outcomes and correlates of TP53 mutations and cancer","journal-title":"Cold Spring Harb. Perspect. Biol.","doi-asserted-by":"crossref"},{"DOI":"10.1038/nrclinonc.2017.151","key":"10.1016/j.lungcan.2025.108891_b0055","year":"2018","issue":"1","author":"Sabapathy","volume":"15","first-page":"13","unstructured":null,"article-title":"Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others","journal-title":"Nat. Rev. Clin. Oncol.","doi-asserted-by":"crossref"},{"DOI":"10.1093/jnci/95.13.961","key":"10.1016/j.lungcan.2025.108891_b0060","year":"2003","issue":"13","author":"Ahrendt","volume":"95","first-page":"961","unstructured":null,"article-title":"p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study","journal-title":"J. Natl Cancer Inst.","doi-asserted-by":"crossref"},{"DOI":"10.1038/sj.onc.1201475","key":"10.1016/j.lungcan.2025.108891_b0065","year":"1997","issue":"24","author":"De Anta","volume":"15","first-page":"2951","unstructured":null,"article-title":"TP53 mutational pattern in spanish and polish non-small cell lung cancer patients: null mutations are associated with poor prognosis","journal-title":"Oncogene","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.lungcan.2025.108891_b0070","year":"1999","issue":"21","author":"Hashimoto","volume":"59","first-page":"5572","unstructured":null,"article-title":"p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas","journal-title":"Cancer Res.","doi-asserted-by":null},{"DOI":"10.1016/j.jtho.2021.08.764","key":"10.1016/j.lungcan.2025.108891_b0075","year":"2022","issue":"1","author":"Saleh","volume":"17","first-page":"76","unstructured":null,"article-title":"Comprehensive analysis of TP53 and KEAP1 mutations and their impact on survival in localized-and advanced-stage NSCLC","journal-title":"J. Thorac. Oncol.","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.lungcan.2025.108891_b0080","year":"2000","issue":"3","author":"Skaug","volume":"6","first-page":"1031","unstructured":null,"article-title":"p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients","journal-title":"Clin. Cancer Res.","doi-asserted-by":null},{"DOI":"10.1038/sj.onc.1202384","key":"10.1016/j.lungcan.2025.108891_b0085","year":"1999","issue":"4","author":"Tomizawa","volume":"18","first-page":"1007","unstructured":null,"article-title":"Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma","journal-title":"Oncogene","doi-asserted-by":"crossref"},{"DOI":"10.1158/1078-0432.CCR-05-1029","key":"10.1016/j.lungcan.2025.108891_b0090","year":"2006","issue":"4","author":"Olivier","volume":"12","first-page":"1157","unstructured":null,"article-title":"The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer","journal-title":"Clin. Cancer Res.","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa073770","key":"10.1016/j.lungcan.2025.108891_b0095","year":"2007","issue":"25","author":"Poeta","volume":"357","first-page":"2552","unstructured":null,"article-title":"TP53 mutations and survival in squamous-cell carcinoma of the head and neck","journal-title":"N. Engl. J. Med.","doi-asserted-by":"crossref"},{"DOI":"10.3389/fgene.2016.00085","key":"10.1016/j.lungcan.2025.108891_b0100","year":"2016","issue":null,"author":"Halvorsen","volume":"7","first-page":"85","unstructured":null,"article-title":"TP53 mutation spectrum in smokers and never smoking lung cancer patients","journal-title":"Front. Genet.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jtho.2016.02.002","key":"10.1016/j.lungcan.2025.108891_b0105","year":"2016","issue":"6","author":"Ma","volume":"11","first-page":"850","unstructured":null,"article-title":"Prognostic and Predictive effect of TP53 Mutations in patients with Non–Small Cell Lung Cancer from Adjuvant Cisplatin–Based Therapy Randomized Trials: a LACE-Bio Pooled Analysis","journal-title":"J. Thorac. Oncol.","doi-asserted-by":"crossref"},{"DOI":"10.1158/1078-0432.CCR-13-2391","key":"10.1016/j.lungcan.2025.108891_b0110","year":"2014","issue":"17","author":"Molina-Vila","volume":"20","first-page":"4647","unstructured":null,"article-title":"Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non–small cell lung cancer","journal-title":"Clin. Cancer Res.","doi-asserted-by":"crossref"},{"DOI":"10.1002/mc.22077","key":"10.1016/j.lungcan.2025.108891_b0115","year":"2015","issue":"2","author":"Lee","volume":"54","first-page":"93","unstructured":null,"article-title":"The influence of TP53 mutations on the prognosis of patients with early stage non‐small cell lung cancer may depend on the intratumor heterogeneity of the mutations","journal-title":"Mol. Carcinog.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ebiom.2020.102990","key":"10.1016/j.lungcan.2025.108891_b0120","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"H. Sun et al., “Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma,” EBioMedicine, vol. 60, 2020.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1016/j.lungcan.2019.04.005","key":"10.1016/j.lungcan.2025.108891_b0125","year":"2019","issue":null,"author":"Assoun","volume":"132","first-page":"65","unstructured":null,"article-title":"Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer","journal-title":"Lung Cancer","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.lungcan.2025.108891_b0130","year":"2023","issue":null,"author":"Mathiot","volume":null,"first-page":null,"unstructured":null,"article-title":"Prognostic impact of TP53 mutations in metastatic non-squamous non-small-cell lung cancer","journal-title":"Clin. Lung Cancer","doi-asserted-by":null},{"DOI":"10.3389/fmolb.2020.602328","key":"10.1016/j.lungcan.2025.108891_b0135","year":"2020","issue":null,"author":"Lin","volume":"7","first-page":null,"unstructured":null,"article-title":"Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and its Association with Tumor Microenvironment of Lung Adenocarcinoma","journal-title":"Front. Mol. Biosci.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.gendis.2020.04.001","key":"10.1016/j.lungcan.2025.108891_b0140","year":"2022","issue":"1","author":"Wang","volume":"9","first-page":"245","unstructured":null,"article-title":"The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC","journal-title":"Genes & Diseases","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(16)32517-X","key":"10.1016/j.lungcan.2025.108891_b0145","year":"2017","issue":"10066","author":"Rittmeyer","volume":"389","first-page":"255","unstructured":null,"article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(16)00587-0","key":"10.1016/j.lungcan.2025.108891_b0150","year":"2016","issue":"10030","author":"Fehrenbacher","volume":"387","first-page":"1837","unstructured":null,"article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41591-018-0134-3","key":"10.1016/j.lungcan.2025.108891_b0155","year":"2018","issue":"9","author":"Gandara","volume":"24","first-page":"1441","unstructured":null,"article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","journal-title":"Nat. Med.","doi-asserted-by":"crossref"},{"DOI":"10.1038/nbt.2696","key":"10.1016/j.lungcan.2025.108891_b0160","year":"2013","issue":"11","author":"Frampton","volume":"31","first-page":"1023","unstructured":null,"article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","journal-title":"Nat. Biotechnol.","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.lungcan.2025.108891_b0165","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"The TP53 Database (R20, July 2019) [Online] Available: https://tp53.isb-cgc.org.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.jtho.2016.10.007","key":"10.1016/j.lungcan.2025.108891_b0170","year":"2017","issue":"2","author":"Lee","volume":"12","first-page":"403","unstructured":null,"article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer—a meta-analysis","journal-title":"J. Thorac. Oncol.","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.21.01626","key":"10.1016/j.lungcan.2025.108891_b0175","year":"2022","issue":"6","author":"Tan","volume":"40","first-page":"611","unstructured":null,"article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","journal-title":"J. Clin. Oncol.","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41571-023-00842-2","key":"10.1016/j.lungcan.2025.108891_b0180","year":"2024","issue":"2","author":"Tuval","volume":"21","first-page":"106","unstructured":null,"article-title":"Pharmacological reactivation of p53 in the era of precision anticancer medicine","journal-title":"Nat. Rev. Clin. Oncol.","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.lungcan.2025.108891_b0185","year":"2003","issue":"20","author":"Olivier","volume":"63","first-page":"6643","unstructured":null,"article-title":"Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype","journal-title":"Cancer Res.","doi-asserted-by":null},{"DOI":"10.1038/sj.onc.1210302","key":"10.1016/j.lungcan.2025.108891_b0190","year":"2007","issue":"15","author":"Petitjean","volume":"26","first-page":"2157","unstructured":null,"article-title":"TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes","journal-title":"Oncogene","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.lungcan.2025.108891_b0195","year":"2024","issue":null,"author":"Schneider","volume":null,"first-page":null,"unstructured":null,"article-title":"Li-fraumeni syndrome","journal-title":"GeneReviews®[Internet]","doi-asserted-by":null},{"DOI":"10.1016/S1470-2045(21)00580-5","key":"10.1016/j.lungcan.2025.108891_b0200","year":"2021","issue":"12","author":"de Andrade","volume":"22","first-page":"1787","unstructured":null,"article-title":"Cancer incidence, patterns, and genotype–phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study","journal-title":"Lancet Oncol.","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41431-020-0638-4","key":"10.1016/j.lungcan.2025.108891_b0205","year":"2020","issue":"10","author":"Frebourg","volume":"28","first-page":"1379","unstructured":null,"article-title":"Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromes","journal-title":"Eur. J. Hum. Genet.","doi-asserted-by":"crossref"},{"DOI":"10.18632/aging.103502","key":"10.1016/j.lungcan.2025.108891_b0210","year":"2020","issue":"14","author":"Zhao","volume":"12","first-page":"14556","unstructured":null,"article-title":"TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapy","journal-title":"Aging","doi-asserted-by":"crossref"},{"DOI":"10.1158/1078-0432.CCR-18-0163","key":"10.1016/j.lungcan.2025.108891_b0215","year":"2018","issue":"22","author":"Biton","volume":"24","first-page":"5710","unstructured":null,"article-title":"TP53, STK11, and EGFR mutations predict tumor immune profile and the response to anti–PD-1 in lung adenocarcinoma","journal-title":"Clin. Cancer Res.","doi-asserted-by":"crossref"},{"DOI":"10.1158/1078-0432.CCR-16-2554","key":"10.1016/j.lungcan.2025.108891_b0220","year":"2017","issue":"12","author":"Dong","volume":"23","first-page":"3012","unstructured":null,"article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","journal-title":"Clin. Cancer Res.","doi-asserted-by":"crossref"},{"DOI":"10.1101/cshperspect.a026294","key":"10.1016/j.lungcan.2025.108891_b0225","year":"2016","issue":"9","author":"Robles","volume":"6","first-page":null,"unstructured":null,"article-title":"Clinical outcomes of TP53 mutations in cancers","journal-title":"Cold Spring Harb. Perspect. Med.","doi-asserted-by":"crossref"},{"DOI":"10.3390/cancers15020429","key":"10.1016/j.lungcan.2025.108891_b0230","year":"2023","issue":"2","author":"Nishikawa","volume":"15","first-page":"429","unstructured":null,"article-title":"Drugs targeting p53 mutations with FDA approval and in clinical trials","journal-title":"Cancers","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41573-022-00571-8","key":"10.1016/j.lungcan.2025.108891_b0235","year":"2023","issue":"2","author":"Hassin","volume":"22","first-page":"127","unstructured":null,"article-title":"Drugging p53 in cancer: one protein, many targets","journal-title":"Nat. Rev. Drug Discov.","doi-asserted-by":"crossref"},{"DOI":"10.1038/nrc.2017.109","key":"10.1016/j.lungcan.2025.108891_b0240","year":"2018","issue":"2","author":"Bykov","volume":"18","first-page":"89","unstructured":null,"article-title":"Targeting mutant p53 for efficient cancer therapy","journal-title":"Nat. Rev. Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41419-022-05431-2","key":"10.1016/j.lungcan.2025.108891_b0245","year":"2022","issue":"11","author":"Palomar-Siles","volume":"13","first-page":"997","unstructured":null,"article-title":"Translational readthrough of nonsense mutant TP53 by mRNA incorporation of 5-Fluorouridine","journal-title":"Cell Death Dis.","doi-asserted-by":"crossref"},{"DOI":"10.3389/fonc.2017.00323","key":"10.1016/j.lungcan.2025.108891_b0250","year":"2018","issue":null,"author":"Zhang","volume":"7","first-page":null,"unstructured":null,"article-title":"Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors","journal-title":"Front. Oncol.","doi-asserted-by":"crossref"},{"DOI":"10.1136/jitc-2021-003027","key":"10.1016/j.lungcan.2025.108891_b0255","year":"2022","issue":"2","author":"West","volume":"10","first-page":null,"unstructured":null,"article-title":"Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial","journal-title":"J. Immunother. Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2413361","key":"10.1016/j.lungcan.2025.108891_b0260","year":"2025","issue":"16","author":"Pich","volume":"392","first-page":"1594","unstructured":null,"article-title":"Tumor-infiltrating clonal hematopoiesis","journal-title":"N. Engl. J. Med.","doi-asserted-by":"crossref"}],"short-title":[],"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S0169500225007834"],"article-number":"108891","content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,2]]},"reference-count":52,"published-online":null,"references-count":52,"special_numbering":"C","short-container-title":["Lung Cancer"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1016/j.lungcan.2025.108891","is_oa":true,"title":"Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials","updated":"2026-01-10T04:46:20+00:00","published_date":"2025-12-29","best_oa_location":{"url":"https://www.lungcancerjournal.info/article/S0169-5002(25)00783-4/pdf","pmh_id":null,"url_for_pdf":"https://www.lungcancerjournal.info/article/S0169-5002(25)00783-4/pdf","url_for_landing_page":"https://doi.org/10.1016/j.lungcan.2025.108891"}}},"created_at":"2026-01-11T11:19:33.869Z","updated_at":"2026-01-11T11:19:33.869Z","tags":[{"paper_doi":"10.1016/j.lungcan.2025.108891","tag_type":"brand","value":"Tecentriq","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2025.108891","tag_type":"category","value":"Respiratory System","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2025.108891","tag_type":"condition","value":"Non-Small Cell Lung Cancer","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2025.108891","tag_type":"generic","value":"atezolizumab","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2025.108891","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2025.108891","tag_type":"modality","value":"Chemotherapy","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2025.108891","tag_type":"modality","value":"PD-L1 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2025.108891","tag_type":"sample_size","value":"n=762","value_numeric":762},{"paper_doi":"10.1016/j.lungcan.2025.108891","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2025.108891","tag_type":"warning","value":"Design is a biomarker post-hoc analysis within two RCTs; patients were not randomized by TP53 status.","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2025.108891","tag_type":"warning","value":"The Poeta classification result lists HR 1.33 with a 95% CI of 1.37–1.77, which appears internally inconsistent and may reflect a typographical error in the source text.","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2025.108891","tag_type":"warning","value":"Timeframe of follow-up and outcome assessment was not reported in the provided text.","value_numeric":null}],"summaries":{"what_studied":"Biomarker analysis of OAK and POPLAR randomized trials in previously treated advanced driver-negative NSCLC assessed whether refined TP53 mutation classes (by coding, Olivier, and Poeta) prognose overall survival and predict benefit from atezolizumab versus chemotherapy using baseline plasma genotyping.","key_result":"Among 762 participants, 49% had TP53 mutations. Binary TP53 mutant status trended to worse OS (adjusted HR 1.15; 95% CI 0.96-1.38; P=.12), while nonsense mutations (adjusted HR 1.71; 95% CI 1.22-2.39; P=.002), non-missense by Olivier (adjusted HR 1.33; 95% CI 1.03-1.74; P=.03), and disruptive by Poeta (adjusted HR 1.33; 95% CI 1.37-1.77; P=.03) were linked to poorer OS; TP53 status did not predict differential ICI vs chemotherapy benefit (interaction P=.45).","practice_takeaway":"Refined TP53 classifications (nonsense/non-missense/disruptive) identify worse-prognosis patients after first-line failure in driver-negative advanced NSCLC, useful for risk stratification and lab reporting. TP53 status should not guide choosing atezolizumab versus chemotherapy in this setting."}},{"doi":"10.1002/cncr.70126","pmid":"41355404","title":"Overall survival according to time‐of‐day of immunochemotherapy for extensive‐stage small cell lung cancer","journal_title":"Cancer","journal_issn":"0008-543X","published_at":"2025-12-08T00:00:00.000Z","url":"https://doi.org/10.1002/cncr.70126","source_score":380,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-01-08","doi":"10.1002/cncr.70126","days":"30","issn":"0008-543X","rank":"3","field":"Clinical Medicine","score":"380","category":"Oncology","categories":["Oncology"],"_categories":["Oncology"]},"pubmed":{"doi":"10.1002/cncr.70126","title":"Overall survival according to time-of-day of immunochemotherapy for extensive-stage small cell lung cancer.","journal":"Cancer","methods":"This retrospective study (LungTime-R02) analyzed 397 patients with ES-SCLC who received first-line anti-PD-L1 (atezolizumab or durvalumab) plus chemotherapy at our center between May 2019 and October 2023. The time of day of administration (ToDA) was calculated as the median infusion time for each patient's first four ICI treatment cycles. To assess its prognostic relevance, hazard ratios (HRs) of earlier progression or death were estimated across multiple ToDA thresholds (11:00-16:30). Propensity score matching (1:2) was applied to balance baseline characteristics.","results":"","abstract":"$32","keywords":["anti‐PD‐L1","chronotherapy","extensive‐stage small cell lung cancer","immune checkpoint inhibitors","immunochemotherapy","time‐of‐day infusion"],"pubmed_id":"41355404","conclusions":"This study provides real-world evidence supporting the survival benefit of earlier immunochemotherapy administration in patients with ES-SCLC. These findings add to the growing body of knowledge on the clinical relevance of circadian timing in cancer treatment.","publication_date":"2025-12-08T00:00:00"},"crossref":{"DOI":"10.1002/cncr.70126","URL":"https://doi.org/10.1002/cncr.70126","ISSN":["0008-543X","1097-0142"],"link":[{"URL":"https://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.70126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"24","score":1,"title":["Overall survival according to time‐of‐day of immunochemotherapy for extensive‐stage small cell lung cancer"],"author":[{"given":"Zhe","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"},{"name":"Department of Pathology School of Basic Medical Science Central South University Changsha China"}]},{"given":"Zhaohui","family":"Ruan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"},{"name":"Third Xiangya Hospital Central South University Changsha China"}]},{"given":"Shidong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"},{"name":"Department of Pathology School of Basic Medical Science Central South University Changsha China"}]},{"given":"Nachuan","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"},{"name":"Graduate Collaborative Training Base of Hunan Cancer Hospital Hengyang Medical School University of South China Hengyang China"}]},{"given":"Li","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"}]},{"given":"Huan","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"}]},{"given":"Jiacheng","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"}]},{"given":"Jun","family":"Deng","sequence":"additional","affiliation":[{"name":"Early Clinical Trial Center Office of National Drug Clinical Trial Institution Hunan Cancer Hospital The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"}]},{"given":"Xue","family":"Chen","sequence":"additional","affiliation":[{"name":"Early Clinical Trial Center Office of National Drug Clinical Trial Institution Hunan Cancer Hospital The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Hunan Cancer Hospital The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"}]},{"given":"Hua","family":"Xiang","sequence":"additional","affiliation":[{"name":"Hunan Cancer Hospital The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"}]},{"given":"Liang","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"}]},{"given":"Gang","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Pathology Xiangya Hospital School of Basic Medical Sciences Central South University Changsha China"}]},{"given":"Yongchang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"},{"name":"Department of Pathology School of Basic Medical Science Central South University Changsha China"},{"name":"Graduate Collaborative Training Base of Hunan Cancer Hospital Hengyang Medical School University of South China Hengyang China"},{"name":"Early Clinical Trial Center Office of National Drug Clinical Trial Institution Hunan Cancer Hospital The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"},{"name":"Furong Laboratory Changsha China"}]}],"issued":{"date-parts":[[2025,12,8]]},"member":"311","prefix":"10.1002","source":"Crossref","volume":"131","archive":["Portico"],"created":{"date-time":"2025-12-08T08:01:06Z","timestamp":1765180866000,"date-parts":[[2025,12,8]]},"indexed":{"date-time":"2025-12-23T10:41:55Z","timestamp":1766486515974,"date-parts":[[2025,12,23]]},"license":[{"URL":"http://onlinelibrary.wiley.com/termsAndConditions#vor","start":{"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000,"date-parts":[[2025,12,8]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$33","language":"en","relation":{},"resource":{"primary":{"URL":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.70126"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-07-18"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-17"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-12-08"}],"deposited":{"date-time":"2025-12-23T10:32:25Z","timestamp":1766485945000,"date-parts":[[2025,12,23]]},"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"published":{"date-parts":[[2025,12,8]]},"publisher":"Wiley","reference":[{"DOI":"10.1016/S1470‐2045(21)00546‐5","key":"e_1_2_11_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1136/jitc‐2023‐008011","key":"e_1_2_11_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.oraloncology.2024.106761","key":"e_1_2_11_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10388‐023‐01006‐y","key":"e_1_2_11_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/hed.27825","key":"e_1_2_11_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jtocrr.2024.100659","key":"e_1_2_11_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clgc.2023.06.004","key":"e_1_2_11_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.annonc.2022.07.1851","key":"e_1_2_11_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ejca.2023.01.007","key":"e_1_2_11_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ebiom.2025.105607","key":"e_1_2_11_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.esmoop.2023.102220","key":"e_1_2_11_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1146/annurev.pharmtox.48.113006.094626","key":"e_1_2_11_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cell.2024.04.015","key":"e_1_2_11_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41586‐022‐05605‐0","key":"e_1_2_11_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.trecan.2019.07.002","key":"e_1_2_11_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1158/0008‐5472.CAN‐24‐2083","key":"e_1_2_11_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jtho.2024.11.011","key":"e_1_2_11_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41571‐024‐00914‐x","key":"e_1_2_11_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.annonc.2019.10.021","key":"e_1_2_11_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140‐6736(19)32222‐6","key":"e_1_2_11_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ccell.2024.01.010","key":"e_1_2_11_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ccell.2020.12.014","key":"e_1_2_11_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/s13045‐025‐01690‐6","key":"e_1_2_11_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.7326/0003‐4819‐147‐8‐200710160‐00010‐w1","key":"e_1_2_11_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470‐2045(17)30074‐8","key":"e_1_2_11_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1158/1541‐7786.MCR‐21‐0786","key":"e_1_2_11_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41590‐024‐01859‐0","key":"e_1_2_11_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cell.2025.03.022","key":"e_1_2_11_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,15]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1002/cncr.70126"],"article-number":"e70126","content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Cancer"],"published-print":{"date-parts":[[2025,12,15]]},"reference-count":28,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,8]]},"references-count":28,"short-container-title":["Cancer"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1002/cncr.70126","is_oa":false,"title":"Overall survival according to time‐of‐day of immunochemotherapy for extensive‐stage small cell lung cancer","updated":"2025-12-09T00:42:45+00:00","published_date":"2025-12-08","best_oa_location":null}},"created_at":"2026-01-08T08:12:02.165Z","updated_at":"2026-01-09T17:12:27.221Z","tags":[{"paper_doi":"10.1002/cncr.70126","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"condition","value":"Extensive-Stage Small Cell Lung Cancer","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"generic","value":"atezolizumab","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"generic","value":"durvalumab","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"modality","value":"Chemotherapy","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"modality","value":"PD-L1 Inhibitor","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"sample_size","value":"n=397","value_numeric":397},{"paper_doi":"10.1002/cncr.70126","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"warning","value":"Abstract does not report absolute PFS/OS durations or event counts; only hazard ratios are provided.","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"warning","value":"Single-center retrospective cohort; generalizability may be limited.","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"warning","value":"Time-of-day cutoff (15:00) was selected after scanning multiple thresholds, which can inflate associations.","value_numeric":null}],"summaries":{"what_studied":"A retrospective single-center cohort (n=397) of extensive-stage small cell lung cancer treated first line with anti–PD-L1 (atezolizumab or durvalumab) plus chemotherapy from May 2019 to October 2023, testing whether time-of-day of infusion (median of first four cycles) relates to PFS and OS.","key_result":"The optimal time-of-day cutoff was 15:00; patients treated before 15:00 had longer PFS and OS. Early administration was independently associated with lower risk: PFS adjusted HR 0.483 (95% CI 0.357–0.654) and OS adjusted HR 0.373 (95% CI 0.265–0.526), consistent in pooled and propensity score–matched cohorts.","limitations":"Retrospective, single-center design. The 15:00 threshold was chosen after testing multiple cutoffs (11:00–16:30), raising risk of overfitting.","practice_takeaway":"For ES-SCLC starting PD-L1–based chemoimmunotherapy, scheduling infusions before 15:00 was linked with better PFS and OS in this real-world cohort. When feasible, earlier-day administration may be reasonable while awaiting prospective confirmation."}}],"initialOffset":17,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"generic","value":"atezolizumab"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Generics","href":"/hub/tag/generic"},{"name":"atezolizumab"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"generic","hub_tag_value":"atezolizumab"}}}]]

Papers